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Foreword 
Antimicrobial Resistance (AMR) is a public health problem of increasing magnitude and 
importance recognized by the United States (US) and the European Union (EU), as well as their 
partner countries. Resistance occurs naturally, but misuse and overuse is rapidly increasing the 
prevalence of hard to treat infections in both humans and animals. At the current pace AMR is 
developing and given the lack of new antimicrobial drugs in development, we could foresee a 
future in which our grandchildren may once again begin to die from complications of a 
mundane infection from a skinned knee or in which patients no longer consistently survive 
routine surgeries. Without the ability to heal infections, medically innovative procedures may be 
beyond our reach. Antimicrobial drugs are tools that have empowered us to push the 
boundaries of our knowledge, and without them, the progress that has defined healthcare in 
the 20th and 21st centuries may be stymied or regress.  
 
Recognizing that AMR is a growing and dangerous public health issue, US President Obama and 
then-President of the EU, Prime Minister Fredrik Reinfeldt from Sweden, established a 
transatlantic taskforce on antimicrobial resistance (TATFAR) on the margins of the US-EU 
summit in 2009. In September 2011, 17 recommendations on AMR were put forth to articulate 
future collaborations between the US and EU. These recommendations fall into three broad 
categories: urgent AMR issues focused on appropriate therapeutic use of antimicrobial drugs in 
the medical and veterinary communities, prevention of both healthcare- and community-
associated drug-resistant infections, and strategies for improving the pipeline of new 
antimicrobial drugs. TATFAR has led to fruitful cooperation between the US and EU that has 
begun to make a tangible difference in the fight against AMR. 
Based on the promise shown by our early cooperation, we decided to renew TATFAR in 2013 
for another two-year term. In addition, we agreed to transfer the Secretariat from the European 
Centre for Disease Prevention and Control (ECDC) to the US Centers for Disease Control and 
Prevention (CDC) for the renewal term. As TATFAR moved into its two-year renewal period, this 
report reviews the progress that has been made for each recommendation and feedback to 
determine whether work toward the recommendation should continue in the future. Work on 15 
of the original TATFAR recommendations and one new recommendation will continue into 2015, 
a strong testament to the benefits of the cooperation between the US and EU.  
 
 
Continuous effort is needed at global and national levels to develop a cross-sectorial approach 
spanning human health, agriculture, food safety, and infection control in healthcare settings to 
effectively contain AMR. Both the US and EU look forward to further, expanded cooperation by 
working together to meet the present and ever-evolving challenges presented by AMR. 
 
           
 
 
 
Dr. Nils Daulaire, TATFAR Co-Chair                  
Assistant Secretary of Global Affairs 
U.S. Department of Health and Human Services 
 
 
 
 
John F. Ryan, TATFAR Co-Chair 
 
Acting Director Public Health Directorate 
 
European Commission 
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Executive summary 
 
The Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) was created in 2009 with the 
goal of improving cooperation between the US and the EU in three key areas: appropriate 
therapeutic use of antimicrobial drugs in medical and veterinary communities, prevention of 
healthcare- and community-associated drug-resistant infections, and strategies for improving the 
pipeline of new antimicrobial drugs. TATFAR identified and adopted 17 recommendations for 
future collaborations between the US and the EU. The implementation of the recommendations 
has been carried out through increased communication; regular meetings and joint workshops; 
and exchange of information and approaches, best practises and methods. 
 
This report summarises the progress and the outcomes of the implementation of the 17 
recommendations, as well as the decision about the future of each recommendation. In addition, it 
also includes one new recommendation. 
 
Each of the recommendations increased communication and collaboration between EU and US 
partners. In addition, the following outputs have been generated or are expected as a result of the 
first TATFAR period (2011-2013): 
− A report summarising the results of a review that identifies a minimum set of common 
indicators to include in the US and the EU country strategies on hospital antimicrobial 
stewardship is expected by September 2014 (recommendation 1); 
− A joint publication summarising the results of a review of the existing methods for 
measuring antimicrobial use in hospital settings is expected by September 2014 
(recommendation 2); 
− A joint publication on the comparison of the results of the U.S and EU point prevalence 
survey on healthcare-associated infections and antimicrobial use in European acute care 
hospitals is expected by December 2014 (recommendation 7); 
− Adoption of Term of References for transatlantic communication of critical events that may 
signify new resistance trends that have global public health implications (recommendation 
8); 
− A joint publication describing the current status and evolution of infection control 
programmes in the EU and in the US (recommendation 10); 
− A joint publication delineating the need for new vaccines for HAIs and which vaccines are 
most needed expected by November 2014 (recommendation 11); 
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− A report on the 2011 workshop, “Challenges and solutions in the development of new 
diagnostic tests to combat antimicrobial resistance” has been published on the TATFAR 
website (recommendation 13); 
− Joint presentations to the scientific community to increase awareness on and promote the 
available funding opportunities on both sides of the Atlantic will continue (recommendation 
14). 
 
Collaboration between the US and the EU has led to an increase in exchanging information, 
understanding of best approaches and practices, and developing peer relationships. While 
significant progress has been made, concern related to AMR continues to grow. Therefore, the 
mandate of the taskforce has been extended for two additional years. The collaboration on, and 
the implementation of, 15 recommendations will continue as previously defined, one 
recommendation has been added, and two recommendations will cease as the path for future 
collaboration was not clear. 
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Introduction 
 
Background on the antimicrobial resistance problem 
 
The introduction of penicillin in the 1940s led to a dramatic reduction in illness and death from 
infectious diseases. However, penicillin-resistant bacteria were isolated from patients soon after the 
drug was introduced. Since then, numerous new antimicrobial1 agents have become available, 
many of which have been rendered ineffective by the remarkable ability of bacteria to become 
resistant through mutation or acquisition of resistance genes from other organisms. When an 
antimicrobial drug is used, the selective pressure exerted by the drug favours the growth of 
organisms that are resistant to the drug’s action. The extensive use of antimicrobial drugs has 
resulted in drug resistance that threatens to undermine the tremendous life-saving power of these 
drugs.  
 
AMR is not a new phenomenon; however, the current magnitude of the problem and the speed 
with which new resistance phenotypes have emerged elevates the public health significance of this 
issue. As a result, only 70 years after their introduction, we are facing the possibility of a future 
without effective antimicrobial drugs for some infections—a future in which operations and 
treatments, such as cancer chemotherapy and organ transplants, could become more dangerous. 
In addition, the scarcity of new antimicrobial agents and the dearth of new agents in the drug 
development pipeline limit treatment options, particularly for patients with infections caused by 
multidrug-resistant (MDR) organisms that occur mainly in healthcare settings. 
 
The societal and financial costs of treating antimicrobial-resistant infections place a significant 
burden on society—a burden that is likely to grow as the number of drug-resistant infections 
increases. Patients infected with drug-resistant organisms are more likely to remain in the hospital 
for a longer period of time and to have a poor prognosis. Furthermore, infections caused by drug-
resistant organisms have a financial burden because of increased costs associated with additional 
doctor visits, longer hospital stays, more expensive drugs and treatment options, and productivity 
losses. Although the total economic cost of AMR is difficult to calculate, in 2009, the ECDC and The 
European Medicines Agency (EMA) estimated that the overall cost for the EU in terms of extra 
health care costs and productivity losses totaled at least EUR 1.5 billion each year1. For the US, 
                                                     
1 Antimicrobial drugs are used to treat infections caused by a wide range of infectious agents including viruses, fungi, and parasites, whereas antibacterial 
or antibiotic drugs are a subset of antimicrobial drugs used to treat bacterial infections. The TATFAR activities are focused on antibacterial resistance and 
consideration of this focus should be given wherever “antimicrobial” is used in this report. 
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estimates are as high as $20 billion in excess direct health care costs, with additional costs to 
society for lost productivity as high as $35 billion a year2. Studies on deaths attributable to a small 
and differing selection of MDR infections show that, each year, these infections result in an 
estimated 25 000 deaths in 29 countries in Europe (5.1 per 100 000 inhabitants) and 23 000 
deaths in the US 2,3. If all, MDR infections and other infections with problematic resistance profiles 
were included in these studies; the estimate of deaths would be inarguably higher. The history and 
scope of the resistance problem has been reviewed extensively elsewhere1,4. 
 
There has been a steady decline in the number of new antibacterial drugs entering the market 
place over the last few decades on both sides of the Atlantic1,3,5. In the setting of continued 
development of AMR and an insufficient pipeline to supply new options, the problem of AMR has 
become more pronounced. Because of the time and expense required to bring a new drug from 
the point of discovery to the market place, we need to respond to the current situation and 
prepare for the future. The goal of such efforts is to ensure that effective treatments are available 
to treat patients with serious infectious diseases, including patients with resistant organisms. The 
recent emergence and spread of Carbapenem-Resistant Enterobacteriacieae (CRE), such as gram-
negative bacteria carrying the New Delhi Metallo beta-lactamase (NDM)6 or Klebsiella 
Pneumonieae Carbapenemase (KPC) resistance genes, are particularly worrisome because 
carbapenems are one of the last line antibiotic drugs to treat MDR infections. In the US, an 
estimated 9 300 health care-associated infections (HAIs) caused by CRE occur, and infections 
caused by carbapenem-resistant Klebsiella spp. and carbapenem-resistant Escherichia coli, the two 
most common types of CRE, lead to approximately 600 deaths each year7. The Europe-wide point 
prevalence survey (PPS) of HAIs and antimicrobial use in European acute-care hospitals (2011-
2012) estimated that 3.2 million HAIs occur each year in the EU, of which 51 901 are associated 
with carbapenem-non-susceptible Enterobacteriaceae (including Klebsiella spp., E. coli, 
Enterobacter spp., and Proteus spp.) and 46 702 are caused by carbapenem-non-susceptible 
Acinetobacter spp.8. The rapid spread of carbapenem-resistant bacteria is a serious threat to 
health care and patient safety worldwide. The consequence of infections with these bacteria is 
fewer treatment options, resulting in increased disease and death. Given that few novel 
antimicrobial agents are likely to become available for clinical use in the short- to medium-term, 
the risks that AMR poses to public health are not difficult to fathom. 
                                                     
2 ECDC/EMEA Joint Technical Report: The bacterial challenge: time to react. 2009. 
3 CDC Report: Antibiotic resistance threats in the United States, 2013. 
4 Boucher, HW et. al. 2009. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infec Dis 48(1): 1-12 
5 Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research. 
London: London School of Economics and Political Science; Available from: http://www.se2009.eu/polopoly_fs/1.16814!menu/standard/file/LSE-ABIF-
Final.pdf. September 2009. 
6 Walsh T et al. Int J Antimicrob Agents. 2010, Suppl 3: S3-14. 
7CDC Report: Antibiotic resistance threats in the United States, 2013. 
8http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf 
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In addition to their central role in human medicine, antimicrobial drugs have been used extensively 
in livestock and poultry since their discovery for the treatment, control, and prevention of animal 
diseases, as well as for production purposes in some regions (e.g., to enhance growth, improve 
feed efficiency). In contrast to human medicine in which treatment is usually directed toward an 
individual patient, entire groups of animals may be treated by the use of medicated feed and 
water. As a result of continued exposure to antimicrobial drugs, the prevalence of resistant bacteria 
in the faecal flora of food animals may be relatively high. Determining the impact of these resistant 
bacteria on human infections is an ongoing challenge as many classes of antimicrobial drugs used 
in food-producing animals have analogues to human therapeutics and are, therefore, capable of 
selecting for similar resistance phenotypes. Of note, a number of these antimicrobial agents are 
also used in companion animal medicine and aquaculture (seafood production). 
 
Developing new drugs alone will not be sufficient to address the growing resistance problem. 
Microbes will always find a way to overcome the therapeutic effect of new drugs; therefore, the 
efficacy of existing drugs needs to be preserved. Promoting the appropriate use of antimicrobial 
agents—use that maximises therapeutic effect while minimising the development of AMR—in both 
human and veterinary medicine is key to reducing selective pressure that leads to the development 
of resistance. Preventing infections, including through vaccination, is essential to control the 
spread of infectious diseases and their associated resistance factors. Another way to decrease 
selective pressure on bacteria in the gut and the environment is to use drugs with a narrow 
spectrum of activity or alternative therapeutic approaches that do not exert selective pressure. This 
type of targeted treatment will remain limited until new rapid diagnostic tests for invasive bacterial 
infections are developed. In addition, rapid diagnostics have the potential to facilitate the clinical 
development of drugs by allowing eligible patients to be identified efficiently. 
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History and scope of the Transatlantic Taskforce on Antimicrobial Resistance 
(2009-2013) 
 
Establishment of the TATFAR 
The growing global threat of AMR was recognised by US President Obama, Swedish Prime Minister 
and then-European Council President Reinfeldt, and European Commission President Barroso at 
the 2009 US–EU summit. The summit declaration called for the establishment of “―a transatlantic 
taskforce on urgent AMR issues focused on three key areas: 1-appropriate therapeutic use of 
antimicrobial drugs in the medical and veterinary communities, 2-prevention of both health care- 
and community-associated drug-resistant infections, and 3-strategies for improving the pipeline of 
new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” 
The TATFAR was constituted on the basis of this declaration. 
 
Composition of the TATFAR 
Membership of the TATFAR is restricted to US government employees and EU civil servants. Nine 
members from each side of the Atlantic were selected on the basis of the areas of expertise 
identified in the summit declaration. A roster of the TATFAR members can be found in Annex B. 
 
Scope of the TATFAR 
AMR is a diverse issue with numerous contributing factors. The work of the TATFAR primarily 
focused on the specific areas identified in the summit declaration. The scope and term of 
references of TATFAR are described in Annex C. 
 
Working structure of the TATFAR 
The initial primary task of the TATFAR was to define specific areas in which enhanced EU–US 
cooperation could have the most significant impact. To accomplish this, three working groups, 
corresponding to the three key areas identified in the summit declaration, were formed. 
 
Recommendations for future collaboration between the US and EU 
Through regular meetings and several public consultations, the members of the TATFAR identified 
a set of 17 recommendations in these key areas for future collaboration between the US and EU. 
The recommendations were adopted on 22 September 2011 and are described in Annex D. 
 
Implementation of the recommendations for future collaboration between the US and EU 
Upon adoption of the 17 recommendations for future collaboration between the US and EU, the 
TATFAR began the process of implementation them. To implement the recommendations, working 
groups were composed and lead agencies, TATFAR implementers, and contributors were chosen. 
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The first TATFAR mandate was set for two years (2011-2013). The timeline and key dates of 
TATFAR are summarised in Annex E. 
 
Review of implementing recommendations and future of the TATFAR 
After this period (2011-2013), TATFAR reviewed the implementation of the 17 recommendations 
and decided that 15 recommendations would continue to be implemented, although some will 
have a modified scope. Two recommendations will cease, and one recommendation has been 
added. On 3 December 2013, the mandate of TATFAR was extended for an additional two years. 
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Recommendations 
 
Key Area I. Appropriate therapeutic use of antimicrobial drugs in human and 
veterinary medicine 
 
Background 
Antimicrobial drugs are critical to human and veterinary health and must be used appropriately to 
avoid unnecessary resistance from developing. Nearly 50% of antimicrobial use is unnecessary, 
inappropriate, or not optimally effective as prescribed9,10. Common types of inappropriate use 
include prescription of antibacterial drugs for viral infections and use of broad-spectrum 
antimicrobial drugs to treat infections in which narrow-spectrum drugs are recommended. In 
November 2013, an EU-wide survey showed that 49% of Europeans believed that antibiotic drugs 
kill viruses and 41% believed that they are effective against colds and the flu11; therefore, patient 
expectations may contribute to inappropriate use of antibiotic drugs in outpatient settings. 
Furthermore, a recent study found an upward trend in the use of broad-spectrum antimicrobial 
drugs to treat acute respiratory infections in which narrow-spectrum drugs are recommended12,13. 
The overuse of antibiotic drugs is contributing to the growing challenges posed by Clostridium 
difficile in many healthcare facilities, as well as the emergence of new resistance genes. Studies 
demonstrate that improving the use of antibiotic drugs in hospitals can not only help reduce rates 
of C. difficile infection and antibiotic resistance, but can also improve individual patient outcomes 
while substantially reducing health care costs14. To combat inappropriate use of antibiotic drugs, 
antimicrobial stewardship programmes and campaigns to promote adherence to treatment 
guidelines are critical in preserving the effectiveness of existing antimicrobial drugs. Both CDC and 
ECDC are active in these key areas; see Annex F for detailed descriptions of ongoing programmes. 
 
Questions regarding the impact of antimicrobial drug use in food-producing animals have been 
raised and debated for many years. A variety of scientific committees, task forces, and 
organisations have studied and published on the matter, beginning with the Swann Report in 1969. 
In 1997, the World Health Organisation (WHO) published the first of several reports on this issue, 
The Medical Impact of Antimicrobial Use in Food Animals15. In 2000, a WHO expert consultation 
resulted in WHO Global Principles for the Containment of Antimicrobial Resistance in Animals 
                                                     
9 Dellit T et al. Clin Infect Dis (2007) 44(2):159-177. 
10 CDC Report: Antibiotic resistance threats in the United States, 2013. 
11 http://ec.europa.eu/health/antimicrobial_resistance/docs/ebs_407_en.pdf 
12 Kronman M et al. Pediatrics (2011) 127;3, 411-417. 
13 http://pediatrics.aappublications.org/content/early/2013/11/12/peds.2013-3260.full.pdf+html 
14 Kallen A et al. Infect Control Hops Epidemio (2009) 30(3):264-72. 
15 http://whqlibdoc.who.int/hq/1997/WHO_EMC_ZOO_97.4.pdf 
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Intended for Food16. During the same time period, many reports on the topic were published by 
European and American scientists, deliberative bodies, and  government agencies. Some 
recommendations appear repeatedly in these reports, including: support for continued monitoring 
of resistance among bacteria from food animals and food of animal origin and continued 
monitoring of use of antimicrobial drugs, and the promotion of responsible use of antimicrobial 
drugs; and requiring veterinary oversight of all antimicrobial drugs use in animals.. To tackle these 
issues, the US Food and Drug Administration (FDA), EMA, and the European Food Safety Agency 
(EFSA) work actively in these key areas; see Annex F for detailed descriptions of on-going 
programmes. 
 
Both the EU and the US have been involved in international work on AMR in Codex Alimentarius, 
the WHO, and the World Organisation for Animal Health (OIE), but bilateral joint activities are 
limited. Several national or regional activities related to a variety of relevant issues, including legal 
provisions, research, animal health programmes, education of animal health professionals, 
marketing authorisation provisions of antimicrobial veterinary medicinal products, prudent use 
guidelines, surveillance of AMR and antimicrobial use, diagnostic development, and off-label use 
have taken place. 
                                                     
16 http://whqlibdoc.who.int/hq/2000/WHO_CDS_CSR_APH_2000.4.pdf 
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Areas of collaboration 
 
 Antimicrobial stewardship in human medicine 
 
Issue: A common way to assess antimicrobial stewardship programmes is needed 
Recommendation 1: Develop common structure and process indicators for hospital antimicrobial 
stewardship programmes 
− Implementers: CDC, ECDC and other stakeholders 
− Timeline: Two to three years from adoption of recommendation 
 
Antimicrobial stewardship is a coordinated programme that implements interventions promoting 
optimal antimicrobial prescribing to limit AMR and to prevent C. difficile infections, an adverse 
event associated with antibiotic use. Antimicrobial stewardship contributes to high quality and 
effective health care by decreasing unnecessary antimicrobial-related diseases, deaths, and costs. 
To effectively promote antimicrobial stewardship, an understanding of the key elements of 
successful stewardship programmes and interventions is needed. A common strategy for the use, 
monitoring, and interpretation of structure and process indicators of antimicrobial stewardship 
would allow meaningful comparisons between the US and EU Member States, as well as among 
institutions and regions. 
 
ECDC and CDC reviewed the current available methods for evaluating hospital antimicrobial 
stewardship programmes in the EU and the US. Despite differences in the structure of and 
requirements for national programmes, ECDC and CDC agreed that a common structure and 
process indicators organized by functions of the stewardship programme’s implementation and 
effectiveness should be developed, followed by a review of the scientific evidence supporting each 
of the proposed indicators. This review would ideally be based on the updated Cochrane 
Collaboration systematic review “Interventions to improve antibiotic prescribing practices for 
hospital inpatients"17 (expected in 2014).  
 
A meeting with key experts from ECDC and CDC, as well as external experts from the US and EU, 
is being discussed. The objective of this meeting would be to review selected structure and 
process indicators from the updated Cochrane Collaboration systematic review and to identify a 
minimum set of indicators that could be included in the US and the EU country strategies to allow 
                                                     
17 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003543.pub3/pdf 
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comparisons among institutions and regions. The results obtained through this review process will 
be summarised and presented in a final report (expected by September 2014). 
 
Future:  Activities under recommendation 1 will continue during the extension of TATFAR with the 
aim to identify a minimum set of common indicators to include in the US and the EU country 
strategies on hospital antibiotic stewardship. 
 
 Surveillance of antimicrobial use in human and veterinary communities 
 
Issue: Methods to measure antimicrobial use in hospitals vary w idely, preventing data 
comparisons 
Recommendation 2: Convene a joint US/EU working group to propose standards for measuring 
antimicrobial use in hospital settings 
− Implementers: CDC, ECDC, and other stakeholders 
− Timeline: Two to three years from adoption of recommendation 
 
Most human antimicrobial use occurs in healthcare settings. CDC and ECDC shared US and EU 
surveillance approaches and methods to measure antimicrobial use in these settings with the 
purpose of improving the comparability of the antimicrobial use data. This comparison requires 
synchronising data sources and methods (i.e. numerator) to generate common measures that can 
easily be compared (e.g., defined daily dose [DDD], days of therapy [DOT], etc.). 
 
The National Healthcare Safety Network (NHSN) meeting in April 2012 (Jacksonville, Florida) and 
the 2nd ECDC meeting of the Antimicrobial Resistance and Healthcare-Associated Infections 
(ARHAI) networks in November 2012 (Berlin, Germany) provided the opportunity to review the 
measurement units and to identify the steps needed to synchronise methods or produce 
comparable data. A first joint US/EU expert meeting was held in June 2013 in Stockholm, Sweden, 
and focused on new ways to have additional types of measures and risk adjustments. A second 
joint US/EU expert meeting will take place in Spring 2014 (date to be confirmed) in Stockholm, 
Sweden, to finalise the review of existing methods for measuring antimicrobial use in hospital 
settings and to investigate whether comparable hospital level measures could be introduced in the 
EU and the US. The results and conclusions of these two meetings will be summarised in a 
scientific article (expected by September 2014). 
 
Future: Activities under recommendation 2 will continue during the extension of TATFAR.  
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Issue: Common measures of antimicrobial use in veterinary medicine are needed in 
order to compare data between the US and EU and follow  trends over time across 
sectors and regions 
Recommendation 3: Collaborate on collection of data on sales and use of veterinary 
antimicrobial drugs in food producing animals 
− Implementers: FDA, EFSA and EMA 
− Timeline: Two to three years from adoption of recommendation 
 
Since the publication of the TATFAR report in 2011, FDA and EMA have been sharing information 
on the developing units for consumption of antimicrobial agents in food-producing animals. The 
European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project18 has recently 
revised its considerations on collecting data on the use of antimicrobial agents per animal species, 
technical units of measurement, and indicators for reporting use of antimicrobial agents in 
animals19. This document discusses how to establish systems to collect reliable and standardised 
data on the use of antimicrobial agents by animal species for the ESVAC database and how to 
report the data, taking into account the differences in dosing between the various antimicrobial 
agents as well as the animal population. This reflection paper was prepared following a 
consultation period during which stakeholders provided input. This document and the annual 
reports20 of the ESVAC project are regularly shared with FDA. The last ESVAC report includes data 
on the sales of veterinary antimicrobial drugs in 2011 in 25 EU/European Economic Area (EEA) 
countries and reveals that, although large differences in the sales and prescribing patterns are 
observed, some Member States reported a decrease in sales. Although it is premature to consider 
this change as representing a definitive trend, if it continues in future years, it could suggest that 
initiatives such as responsible-use campaigns, restrictions of use, and increased awareness in EU 
Member States are starting to have an impact in terms of reducing the overall sale of antimicrobial 
drugs in the veterinary sector. As a next step, ESVAC is working on the collection of use data by 
species as detailed in the above-mentioned reflection paper; the FDA and other stakeholders will 
be informed of the progress of this task. 
 
FDA has exchanged views with EMA on current activities at the annual meeting of ESVAC project 
and has discussed data collection systems with representatives from the French Agency for Food, 
Environmental and Occupational Health & Safety (ANSES). In 2012, FDA solicited broad public 
                                                     
18 ESVAC web page: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000302.jsp&mid=WC0b01ac0580153a00&jsenabled=
true 
19 ESVAC reflection paper: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/12/WC500136456.pdf 
20 European Medicines Agency, European Surveillance of Veterinary Antimicrobial Consumption, 2013. 
'Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011' (EMA/236501/2013) 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/10/WC500152311.pdf  
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comment on enhancements to the existing requirements related to reporting antimicrobial drug 
sales/distribution data, as well as input on alternative methods for monitoring antimicrobial use in 
food-producing animals. In September 2013, FDA sought additional public input on a new 
proposed format for the annual summary and expects to use the enhanced format when it 
summarizes the data reported for 2012. Also, members of the EMA and FDA presented at the OIE 
Global Conference on the Responsible and Prudent Use of Antimicrobial Agents for Animals, which 
amongst other subjects addressed the collection of data on antimicrobial consumption in animals.  
 
Future: Activities under recommendation 3 will continue during the extension of TATFAR. FDA 
and EMA will confer regularly to exchange updates on the status of efforts to collect data on sales 
and use of veterinary antimicrobial drugs in food producing animals. 
 
 Risk analysis of foodborne antimicrobial resistance 
 
Issue: Methods for analysing the risk of AMR in foodborne pathogens vary w idely 
Recommendation 4: Collaborate on implementation of the Guidelines for Risk Analysis of 
Foodborne Antimicrobial Resistance prepared by Codex Alimentarius 
− Implementers: FDA, EFSA, EMA, and DG SANCO 
− Timeline: One to two years from adoption of recommendation 
 
FDA, EFSA, EMA, and DG SANCO are collaborating in order to implement the Guidelines for Risk 
Analysis of Foodborne Antimicrobial Resistance prepared by Codex Alimentarius21.  
 
The FDA and EMA maintain regular bilateral meetings that include discussions on guidelines and 
recommendations for authorisation of antimicrobial drugs for use in veterinary medicine. A concept 
paper on a guideline for AMR risk assessment was adopted by The Committee for Medicinal 
Products for Veterinary Use (CVMP) at EMA; this concept paper will lead to a guidance document 
that will use as one of its pillars the previously mentioned Codex Alimentarius guidance and will 
include cross-reference to FDA guidelines22 on risk assessment of antibiotic drugs.  
 
During 2011, several reference documents related to antimicrobial drugs were produced by high-
level authorities, including a report by the European Commission23 and a guideline by the Codex 
                                                     
21 Codex Guidelines for Risk Analysis of Foodborne Antimicrobial Resistance (CAC/GL 77- 2011) 
https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CEEQFjAA&url=http%3A%2F%2Fwww.codexalimentarius.org%2Finput
%2Fdownload%2Fstandards%2F11776%2FCXG_077e.pdf&ei=ugmCUpzxOe-N7AbPrYGIAg&usg=AFQjCNGiZSR1bR815R-
NJ7jzWDgmqW1IUQ&bvm=bv.56146854,d.ZGU  
22 FDA guideline #152 (Evaluating the safety of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health 
concern) http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052519.pdf  
23 http://ec.europa.eu/dgs/health_consumer/docs/communication_amr_2011_748_en.pdf 
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Alimentarius Commission in the US24. More recently, a scientific opinion on carbapenem-resistance 
in food animal ecosystems from the BIOHAZ Panel in EFSA was published25.  
 
The FDA, in collaboration with the Government of Costa Rica, conducted a workshop to discuss the 
implementation of the Codex AMR Guidelines in August 2012. Representatives from 16 Latin 
America countries attended this workshop. In addition, the FDA Center for Veterinary Medicine 
discussed FDA’s strategy for addressing AMR issues, especially with regard to prudent use of 
antimicrobial drugs in veterinary medicine. 
 
Much debate is currently focused on the extent to which AMR that occurs as a result of the use of 
antimicrobial drugs in food producing animals contributes to the overall risks to humans. Greater 
clarity on the scale and scope of transfer of resistance is essential to address gaps in our 
understanding of risks arising from different use practices. This information will ensure that 
appropriate control measures are put in place that balance the need to retain an adequate 
therapeutic arsenal to treat infectious diseases in animals against the need to limit the risk to 
humans. 
 
Future: Activities under recommendation 4 will continue during the extension of TATFAR. The 
implementers will consider if additional activities to promote transatlantic cooperation in the area 
of controlling foodborne AMR could be initiated during this extension. In addition, on reviewing this 
recommendation, the implementers recognised that the extent and mechanisms of transmission of 
AMR from animals to man remain poorly understood. A new recommendation was therefore 
agreed specifically to identify and address the knowledge gaps in this area. 
 
New Recommendation: 
Issue:  Antibiotic use in animals can select for antimicrobial resistance that may 
represent a risk to man either through direct infection by resistant bacteria or by the 
transfer of resistance determinants to other bacteria.  
Recommendation 18: Establish a joint working group of international subject matter experts to 
identify key knowledge gaps in understanding the transmission to man of antimicrobial resistance 
arising as a result of the use of antimicrobial drugs in animals and on the development of effective 
intervention measures to prevent this transmission, including the development of alternatives to 
antimicrobial drugs.  
 
                                                     
24 Guidelines for Risk Analysis of Foodborne Antimicrobial Resistance (CAC/GL 77- 2011) 
25 http://www.efsa.europa.eu/en/efsajournal/pub/3501.htm 
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- Implementers: FDA, CDC, USDA, EFSA, EMA, ECDC, DG SANCO, and DG RTD 
- Timeline: One year after adoption of recommendation  
 
The impact that the use of antibiotic drugs in animals has on the risk to man from antimicrobial 
resistance needs to be better understood. The use of antibiotic drugs in animals selects for 
antimicrobial resistance; however,  the mechanism by which this resistance may be transferred to 
man and the extent of the threat that this represents to human health is less clear. Likewise, 
different control strategies to limit to the risk to man from the use of antibiotic drugs in animals 
have been developed and a wide variety of alternatives to the use of antibiotic drugs are under 
development and evaluation. Adopting a ”one health” approach, whereby expertise is brought 
together from both the human and veterinary domains, the working group will consider all uses of 
antimicrobial drugs in animals and will examine the evidence linking the resistance arising as a 
result of this use to infections in man with resistant organisms. The group will consider existing 
control strategies to limit the emergence and spread of antimicrobial resistance as well as the 
development of alternatives to antimicrobial drugs. The working group will identify the gaps in 
knowledge that exist and will develop concrete recommendations for filling these knowledge gaps, 
including suggesting specific research studies.  
 
Issue: Methods to promote appropriate use of antimicrobial drugs in veterinary 
communities vary in the US and in EU Member States 
Recommendation 5: Enhance information sharing on approaches to promote appropriate use in 
veterinary communities 
− Implementers: EMA, DG SANCO, FDA, EFSA, and other stakeholders 
− Timeline: Within two years of adoption of recommendation 
 
EMA, DG SANCO, FDA, EFSA, and other stakeholders are working to enhance information sharing 
on approaches to promote appropriate use in veterinary communities.  
 
Over the past few years, the CVMP at EMA has produced recommendations on prudent use with a 
particular emphasis on critically important antimicrobial drugs. 
 
Information on prudent use is available on the EMA and FDA web sites and is regularly discussed 
and shared during bilateral discussions. Both EMA and FDA also collaborate with the WHO Advisory 
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Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) and OIE26 on this topic; 
EMA has had additional engagement with WHO27. 
 
In 2010, FDA announced a strategy to promote the judicious use of antimicrobial drugs in food-
producing animals by phasing out production uses of antimicrobial drugs that are important in 
human medicine and phasing in veterinary oversight of the remaining therapeutic uses of these 
products. In December 2013, FDA implemented this strategy28, which recommends that drug 
sponsors phase in these changes over a three-year timeframe. 
 
EMA is also providing evidence-based advice on the use of antimicrobial drugs in veterinary 
medicine, as requested by the European Commission (EC)29. The latest of those recommendations 
refer to the antibiotic drugs colistin and tigecycline30. The ESVAC project has noted during the last 
years that many of the participating countries have started to implement actions to promote 
responsible use of antimicrobial drugs in animals. In addition, EMA has started to consider the role 
that companion animals may play and the CVMP has therefore produced a reflection paper on the 
risk of AMR transfer to humans from companion animals31. This document addresses the risk for 
emergence and transmission of AMR from contact with companion animals (e.g., dogs, cats, 
horses, etc.) so that appropriate risk management measures can be adopted during authorisation 
of antimicrobial drugs for companion animals. 
 
DG SANCO is finalising the drafting of the guidelines for prudent use of antimicrobial drugs in 
veterinary medicine. The purpose of the guidelines is to provide recommendations and practical 
guidance on the development of strategies and actions by Member States in order to promote and 
strengthen the prudent use of antimicrobial drugs, especially antibiotic drugs, in veterinary 
medicine. The Guidelines supplement existing legal provisions in the EU and, in order to make the 
recommendations as practical as possible, different EU Member States' approaches are provided as 
examples and possible sources of inspiration for other Member States. 
 
Future: Activities under recommendation 5 will continue during the extension of TATFAR. The 
implementers will confer regularly to share approaches to promoting appropriate use in veterinary 
communities. 
                                                     
26 Oie Global Conference On The Responsible And Prudent Use Of Antimicrobial Agents For Animals 
http://www.oie.int/eng/A_AMR2013/Recommendations.htm 
27WHO booklet Tackling antibiotic resistance from a food safety perspective in Europe: 
http://www.euro.who.int/__data/assets/pdf_file/0005/136454/e94889.pdf  
28 http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM299624.pdf 
29 http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/04/WC500142070.pdf  
30 Colistin http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/07/WC500146813.pdf and tigecycline (glycylcyclines) 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/07/WC500146814.pdf  
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 Campaigns to promote appropriate use in human medicine 
 
Issue: Campaigns to promote appropriate antimicrobial use must be periodically 
updated based on effectiveness data and societal factors 
Recommendation 6: Establish an EU–US working group to assess the evidence for effectiveness 
of communications tools in promoting behaviour change to increase appropriate use and to 
develop joint priorities 
− Implementers: CDC and ECDC 
− Timeline: Within two years of adoption of recommendation 
 
Representatives from the US Get Smart Campaign and European Antibiotic Awareness Day have 
met through quarterly conference calls to develop joint priorities and share information about their 
respective work on prudent antibiotic use campaigns. These activities have focused on 4 keys 
areas: (1) to share published and unpublished information assessing the evidence for effectiveness 
of communications tools in promoting behaviour change to increase appropriate use; (2) to share 
information regarding annual campaign development, including objectives, targets, strategies and 
evaluation; (3) to prepare joint initiatives promoting antibiotic awareness in the run up to Get 
Smart About Antibiotics Week/Antibiotic Awareness Day, (4) to identify opportunities for colleagues 
to participate in key educational meetings linked to promoting behaviour change to increase 
appropriate use. 
 
Every year since 2010, CDC and ECDC agreed to launch both of their campaigns during the week 
of 18 November. Since 2012, Canada and Australia have also aligned the timing of their national 
prudent antibiotic use campaigns. In the area of social media, there have been several coordinated 
actions and joint activities since 2012, e.g., posting links on campaign websites and participation in 
the respective Twitter chats or joint tweets. 
 
In 2013, ECDC and CDC published a joint editorial entitled “Global collaboration essential to spread 
the message on prudent antibiotic use” on prudent antibiotic use campaigns in the US and Europe, 
as well as in Canada and Australia in Lancet Infectious Diseases32. On 18 November 2013, both 
ECDC and CDC took part in the first extended global Twitter conversation with global partners 
(e.g., Canada and Australia). This Twitter conversation was based on a Twitter chat starting in 
Australia and ending on the west coast of North America using the same account and the same 
hashtag. 
 
                                                     
32 Earnshaw S et al. Lancet Infect Dis. 2013 Dec;13(12):1003-4. 
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Future: Activities under recommendation 6 will continue during the extension of TATFAR, 
Representatives from the US Get Smart Campaign and European Antibiotic Awareness Day will 
continue to discuss the coordination of annual joint activities and share lessons learned. With 
increasing calls for a Global Antibiotic Awareness campaign, ECDC and CDC will also consider 
broadening international participation in these campaigns, adding additional countries for this 
important collaboration on antibiotic drugs awareness.  
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Key Area II. Prevention of drug resistant infections 
 
Background 
The burden of healthcare-associated infections (HAIs) has increased over the past few decades 
due to the increase in immunocompromised and elderly patients, increasing use of invasive 
indwelling devices such as catheters, more complex hospital environments, and inadequate 
infection control measures. Antimicrobial resistance has emerged in virtually all healthcare-
associated (nosocomial) pathogens, and most novel resistance factors first surface in healthcare 
facilities. Furthermore, resistant bacteria are also causing infections in the community with 
increasing frequency. The European-wide point prevalence survey of HAIs and antimicrobial use in 
European acute care hospitals (2011-2012) confirms that HAIs represent a major public health 
problem. ECDC estimates that on any given day, about 80 000 patients have at least one HAI (i.e., 
one in 18 patients in a European hospital has an HAI and one in three patients receive at least one 
antimicrobial agent on any given day33). Prevention of drug-resistant infections requires that the 
transmission of drug-resistant bacteria between patients be interrupted. Surveillance is an 
important tool to identify populations where drug-resistant reservoirs and infections occur and to 
assess the effectiveness of infection control interventions to prevent the dissemination of the 
bacteria to new persons and populations. In many cases, effective infection control interventions 
are known, but implementation requires adequate training of healthcare professionals and 
educational campaigns for both healthcare professionals and the general public. In other cases, 
identifying effective infection control interventions requires additional research. 
                                                     
33 http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf 
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Areas of collaboration 
 
 Surveillance of drug-resistant infections 
 
Issue: Methods for collecting information on Healthcare-Associated Infections (HAIs) 
vary w idely 
Recommendation 7: Consultation and collaboration on a point-prevalence survey for HAIs   
− Implementers: CDC and ECDC 
− Timeline: Within three years of adoption of recommendation 
 
Since 2009, CDC and ECDC have attempted to harmonise key methods related to point prevalence 
surveys (PPS) of HAI and antimicrobial use. Although the ECDC and CDC protocols are not 
identical, additional variables were added to both protocols to enable comparison of results. CDC34 
and ECDC35 completed their national PPS of HAIs and antimicrobial use in acute care hospitals in 
2011 and 2012, respectively, providing national estimates of HAI rates and of antimicrobial use 
and information about the epidemiology of infections. During the process, CDC and ECDC also 
shared the preliminary results of their respective PPSs with each other. CDC and ECDC jointly 
presented the results of their PPSs at the symposium on “Are prevalence surveys still useful for 
healthcare-associated infections surveillance?” of the 52nd Interscience Conference on Antimicrobial 
Agents and Chemotherapy (ICAAC) Conference (11 September 2012, San Francisco, US) and at 
the 2nd ECDC meeting of the antimicrobial resistance and healthcare-associated infections (ARHAI) 
networks (26-28 November 2012, Berlin, Germany). During the ECDC PPS evaluation meeting (17-
18 September 2013, Stockholm, Sweden), CDC and ECDC agreed to further collaborate and 
discuss potential changes to the US and EU protocols for the future PPSs. CDC is considering 
conducting another PPS of HAIs and antimicrobial use in acute care hospitals in 2014-2015, and 
ECDC will organise a second EU-wide PPS in all EU Member States in 2016–2017. Furthermore, 
CDC is in the planning phase of a pilot prevalence survey of HAIs and antimicrobial use in nursing 
homes and is currently working with EU investigators to use a similar method as the ECDC-funded 
Healthcare-Associated Infections in Long-Term Care Facilities (HALT) project. 
 
Differences in the sources of information and methods used in generating HAI burden estimates 
make drawing comparisons between the US and the EU data difficult at this time. A meeting 
bringing together key experts from ECDC and CDC to assess the differences in HAI epidemiology 
and priorities between the US and EU and their impact is under discussion. A major output for this 
                                                     
34http://www.cdc.gov/hai/eip/antibiotic-use.html 
35http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf 
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recommendation will be a joint publication on the comparison of the EU PPS results and the CDC 
PPS results (expected by December 2014). 
 
Future: ECDC and CDC will continue to further discuss potential changes to the US and EU 
protocols for future PPSs. 
 
Issue: Public health officials need to be kept informed of emerging resistance trends to 
be prepared to respond appropriately  
Recommendation 8: Develop a process for transatlantic communication of critical events that 
may signify new resistance trends with global public health implications 
− Implementers: CDC and ECDC 
− Timeline: Within two years of adoption of recommendation 
 
Timely transatlantic communication and common actions are fundamental to respond to emerging 
threats and critical trends attributable to AMR. To allow for timely communication and for proper 
dissemination of information within the US, the EU, partner public health agencies, and ministries 
of health, CDC and ECDC drafted and approved terms of reference (ToR) on how international 
communication and actions about critical AMR surveillance results will occur and which type of 
information should be communicated. The ToR describes a procedure for notification when novel 
resistant phenotypes are identified, as well as quarterly conference calls in which CDC and ECDC 
subject matter experts discuss new AMR data and critical trends. These calls were initiated in 2012 
and allow experts to exchange information on resistance but also on surveillance programs and 
protocols. As a result, each agency has gained better insight into the AMR situation and is 
fostering new collaborations. Topics that have been discussed include surveillance programs for 
resistant gram-negative bacteria, vancomycin-resistant Staphylococcus aureus, CRE, and drug-
resistant Neisseria gonorrhoeae. 
 
Future: Communication under recommendation 8 will continue as defined in the approved ToR 
during the two-year extension of TATFAR. 
 
Issue: Susceptibility criteria differ in the US and EU, making comparison of resistance 
rates difficult 
Recommendation 9: Encourage efforts to harmonise, to the extent possible, interpretive criteria 
for susceptibility reporting of bacterial isolates across surveillance programmes in the US and EU 
− Implementers: CDC, ECDC, EFSA, FDA, EU Member States, EU reference laboratory for 
antimicrobial resistance, and other stakeholders 
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− Timeline: Within two years of adoption of recommendation 
 
ECDC, CDC, EMA, FDA, and EFSA are using epidemiologic cut-off (ECOFFs) values for sensitive 
detection of acquired and mutational resistance in a variety of organisms (bacteria and fungi). 
ECOFFs distinguish between isolates with and without phenotypically detectable resistance 
mechanisms whereas clinical breakpoints distinguish between organisms that can and cannot be 
treated with the agent in question. ECOFFs can be used for the purpose of reporting harmonized 
surveillance results as described in this recommendation. The setting of ECOFFs requires 
standardised methods. In addition, for each organism and agent, MIC distributions from many 
investigators must coincide. TATFAR has agreed to encourage harmonisation of ECOFFs and MIC 
distributions of organisms of human, veterinary, and food safety importance. Criteria for a 
common MIC database and for the setting of ECOFFs need to be established. There is a need for 
swift progress since EFSA is already recommending the use of ECOFFs for measuring resistance in 
several pathogens and the U.S National Antimicrobial Resistance Monitoring System (NARMS) is 
adopting ECOFFs for reporting the results of Campylobacter monitoring beginning with data 
collected in 2012 and discussions are ongoing for adopting ECOFFs for reporting Salmonella 
results. 
 
Future: Activities under recommendation 9 will continue during the extension of TATFAR. 
 
 Prevention strategies 
 
Issue: Methods for the evaluation of hospital infection control programmes vary 
w idely 
Recommendation 10: Convene a workshop bringing together public health experts from the US 
and EU to develop consensus evaluation tools for hospital infection control programmes 
− Implementers: CDC and ECDC 
− Timeline: Within two years of adoption of recommendation 
 
Hospital infection control programmes, which include effective infection control interventions, are 
critical to prevent and control the spread of bacteria, HAIs, and hospital outbreaks. Effective 
infection control programmes rely on good implementation of infection control measures, adequate 
training of healthcare professionals, and educational campaigns for healthcare professionals and 
the general public as well as the involvement of hospital administration. 
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CDC and ECDC reviewed the evolution of the culture of infection control in US and EU Member 
States and the available structure and process indicators for evaluating and monitoring hospital 
infection control programmes. The indicators used at the national and hospital programmes were 
not the same in the EU and the US, and facilities in the EU and US are at different stages in 
implementing infection control components. Furthermore, the US developed structures and 
process indicators linked to incentives and reimbursements, which are not common practises in the 
EU, with the exception of some EU Member States. Because the drivers and programmes in the US 
and in many EU Member States are different, CDC and ECDC agreed that reaching a consensus on 
common structure and process indicators for hospital infection control programmes would not be 
possible. The planned workshop was, therefore, cancelled and a joint peer-reviewed article was 
suggested. This article would describe the current status and evolution of infection control 
programmes in the EU and the US and would aim to raise awareness on this issue. 
 
Future: Due to incompatibilities in the evaluation methods for hospital infection control 
programmes in the US and EU, activities under recommendation 10 will cease following completion 
of the article. 
 
Issue: Surveillance data are needed to inform development strategies for vaccines 
targeting HAIs and to evaluate the impact of such vaccines after their introduction  
Recommendation 11: Develop a transatlantic strategy to facilitate vaccine development for HAIs 
− Implementers: CDC, DG RTD, and ECDC 
− Timeline: Two to three years from adoption of recommendation 
 
Candidate vaccines to prevent infection with common HAIs, including MRSA and C. difficile have 
the potential to significantly reduce the prevalence of antimicrobial-resistant infections and 
associated diseases, deaths, and costs.  
 
CDC and ECDC identified the existing initiatives to facilitate developing candidate vaccines to 
prevent infection with common HAIs. CDC and ECDC agreed to produce a joint peer-reviewed 
article delineating the need for new vaccines to address HAIs, including which vaccines are most 
needed and which patient populations would most benefit from different vaccines (expected by 
November 2014). This information can be used by vaccine developers as they select vaccine 
candidates, determine which patient populations to target, and design feasible clinical 
development programmes.  
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Future: Since CDC and ECDC use different models to interact with the vaccine industry, a 
common strategy could not be forged. Activities under recommendation 11 will cease. 
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Key Area III. Strategies to improve the pipeline of new antibacterial drugs for use in 
human medicine 
 
Background 
Government agencies on both sides of the Atlantic recognise the critical need for the development 
of new drugs to treat antimicrobial-resistant infections and are working to foster antibacterial 
research and development and facilitate the approval of new safe and effective antibacterial drugs 
through a variety of mechanisms. A number of factors contributing to the decline in antibacterial 
drug development have been discussed extensively36. A number of challenges are inherent to 
developing new antibacterial drugs. The recommendations describe specific efforts to overcome 
some of the challenges that are encountered when developing a new antibacterial drug to provide 
therapeutic options to treat patients’ infections. 
 
The US National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes 
of Health (NIH), and the Directorate-General for Research and Innovation (DG RTD) at the 
European Commission have issued calls for proposals focused on developing vaccines, drugs, and 
rapid diagnostic tests for resistant pathogens of concern. In addition, NIH/NIAID offers a broad 
array of preclinical and clinical services designed to fill gaps in drug development and lower the 
economic risk of antimicrobial drug development. At both the FDA and the EMA, effort has been 
invested in developing updated recommendations on the most appropriate clinical trial designs for 
evaluating antibacterial drugs. Several of these guidance documents were recently published and 
others are under development. More detailed descriptions of ongoing activities to stimulate 
antibacterial drug development pipeline can be found in Annex F. 
                                                     
36Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research. 
London: London School of Economics and Political Science; Available from: http://www.se2009.eu/polopoly_fs/1.16814!menu/standard/file/LSE-ABIF-
Final.pdf. September 2009. 
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Areas of collaboration  
 
 Incentives to stimulate the development of new antibacterial drugs for use in 
human medicine 
 
Issue: New antibacterial drugs are needed now, but their development is inherently 
difficult because of the biology of these infections and potentially lower economic 
returns when compared w ith other therapeutic areas  
Recommendation 12: Policymakers should strongly consider establishing significant incentives 
to stimulate antibacterial drug development. 
 
Several meetings have been organised by different stakeholders around possible incentives to 
stimulate antibacterial drug development (e.g. Chatham House Conference on AMR, 3-4 October 
2013, London, UK).  
 
In the EU, in the context of the Innovative Medicines Initiative (IMI), a call has been launched for 
a project aimed at developing new business models for antibacterial drugs taking into 
consideration the option of delinking return on investment from sales volumes.  
 
In the US, the Generating Antibiotic Incentives Now (GAIN) Act was signed into law in July 2012. 
GAIN provides for fast track designation, priority review, and additional marketing exclusivity in the 
US for certain qualifying antibacterial and antifungal drugs for the treatment of serious or life-
threatening infections. FDA is collaborating with the Office of the Assistant Secretary for Planning 
and Evaluation of the Department of Health and Human Services on a study to evaluate the 
economics of antibacterial drugs, diagnostic devices, and vaccines for bacterial diseases and to 
evaluate the potential role of incentives to promote their development. 
 
Future: FDA and EMA will continue to share information on new incentives available to drug 
developers on both sides of the Atlantic. 
 
 Research to support the development of new antibacterial drugs 
 
Issue: Antimicrobial resistance research is a rapidly moving field w ith global 
implications 
Recommendation 13: Increase communication between US and EU research agencies to 
identify common scientific challenges that may represent opportunities for collaboration.  
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− Implementers: NIH and DG RTD 
− Timeline: within one year of adoption of recommendation 
 
Program officials from NIH/NIAID and DG RTD hold periodic teleconferences to exchange 
information on ongoing and planned programs and to identify areas in which further discussion 
and collaboration may be warranted. One such area identified during the initial stage of TATFAR 
was the development of rapid diagnostics to enable appropriate use of antimicrobial drugs, as well 
as more feasible antibacterial drug development programmes.  
 
The Joint EU-US workshop “Challenges and Solutions in the Development of New Diagnostic Tests 
to Combat Antimicrobial Resistance” co-organised by the NIH/NIAID and the DG RTD, was held in 
September 2011. The workshop aimed to identify factors negatively impacting development, 
approval, introduction, and appropriate use of new diagnostic tools for invasive bacterial infections 
in both inpatient and outpatient settings. It also addressed the role of diagnostic tools in the 
development of novel antibacterial drugs and the challenges in development of companion 
diagnostics by drug developers37.  
 
In conjunction with the 2013 European Society of Clinical Microbiology and Infectious Diseases 
meeting (ESCMID), NIAID coordinated discussions between NIH and EC-funded investigators 
conducting similar clinical trials on the optimal use of colistin for the treatment of MDR gram-
negative infections. These trans-national discussions continued at the 1st International Conference 
on Polymyxins (2–4 May, 2013, Prato, Italy), which brought together US and EU investigators to 
share experiences with the polymyxins, including clinical trials designed to define their optimal use. 
 
Future: NIH/NIAID and DG RTD will continue to share information about scientific priorities in the 
area of AMR and when appropriate, bring specific scientific communities together around specific 
research topics of particular interest. 
 
Issue: Investigators should consider funding sources and research resources on both 
sides of the Atlantic to support AMR research and antibacterial product development 
efforts 
Recommendation 14: Publicise funding opportunities to the EU and US research communities  
− Implementers: NIH/NIAID and DG RTD 
− Timeline: within one year of adoption of recommendation 
 
                                                     
37 http://ecdc.europa.eu/en/activities/diseaseprogrammes/TATFAR/news/Pages/TATFAR_Workshop.aspx 
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Program Officials from NIH/NIAID and DG RTD have given two joint presentations at international 
meetings, the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 
meeting (31 March–2 April 2012, London, UK) and the1st International Conference on Polymyxins 
(2–4 May, 2013, Prato, Italy). During these presentations, resources available to investigators on 
both sides of the Atlantic, as well as the communication and collaboration efforts under TATFAR, 
were highlighted. 
 
Additionally, efforts have been made to use the websites of NIH/NIAID, DG RTD, and TATFAR to 
publicise calls for proposals and other resources for researchers on both sides of the Atlantic. 
These efforts will be refined as the TATFAR website migrates from the ECDC-based system to the 
CDC-based system. 
 
In 2012, the European Commission together with the European Federation of Pharmaceutical 
Industries and Associations, through their joint undertaking, the Innovative Medicines Initiative 
(IMI)38, launched ”New Drugs for Bad Bugs” a major programme for combatting antibiotic 
resistance. This programme provides an avenue for leading academics, small and medium-sized 
enterprises, and major pharmaceutical companies to join forces to tackle AMR and to speed up the 
delivery of much-needed new antibiotic drugs to patients. 
 
The Joint Programming Initiative on AMR (JPIAMR)39, launched in 2012, pools national research 
efforts to combat AMR within 17 European countries, Israel, and Canada. The JPI AMR has 
developed a strategic research agenda and issues transnational research calls. 
 
In 2013, NIAID launched the Leadership Group for a Clinical Research Network on Antibacterial 
Resistance (ARLG), a major new AMR effort modelled after the NIAID HIV/AIDS Clinical Trials 
Networks. The ARLG has developed a research agenda identifying the most important clinical 
questions in antibacterial resistance, and clinical studies/trials to address these questions are being 
solicited from the global AMR research community.  
 
Future: NIH/NIAID and DG RTD will continue to give joint presentations to the scientific 
community to make them aware of the numerous funding opportunities available to them. In 
addition, the new TATFAR website will provide convenient links to current and future funding 
opportunities in the US and EU. 
 
                                                     
38 http://www.imi.europa.eu/ 
39 http://www.imi.europa.eu/ 
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 Regulatory approaches for antibacterial products 
 
Issue: Antibacterial drug development programmes that satisfy regulatory 
requirements in both the US and EU could facilitate antibacterial drug development 
Recommendation 15: FDA and EMA will discuss ways to facilitate the use of the same clinical 
development programme to satisfy regulatory submissions to both agencies  
− Implementers: FDA and EMA 
− Timeline: within one year of adoption of recommendation 
 
FDA and EMA have been discussing recommendations on clinical trial designs for studying new 
antibacterial drugs. Furthermore, EMA and FDA representatives have participated in meetings to 
address approaches to antibacterial drug development on both sides of the Atlantic. The two 
agencies have been engaged in providing scientific advice to drug developers to help outline 
programs that will satisfy requirements for the US and EU. EMA and FDA recommendations on 
clinical trial designs for studying new antibacterial drugs have been published in EMA’s Guideline 
on the evaluation of medicinal products indicated for treatment of bacterial infections (2012)40 and 
in a number of FDA guidance documents41. 
 
Future: FDA and EMA will continue to work to facilitate the use of the same clinical development 
programme to satisfy regulatory submissions to both agencies. 
 
Issue: Enhanced communication between FDA and EMA on issues such as product 
review  and emerging drug safety issues could be beneficial 
Recommendation 16: Establish regular meetings between FDA and EMA to discuss common 
issues in the area of antibacterial drug development and regulation 
− Implementers: FDA and EMA 
− Timeline: within one year of adoption of recommendation 
 
EMA and FDA have held periodic teleconferences focused on approaches to facilitate trials that are 
feasible, while ensuring the safety and efficacy of new antibacterial drugs, on at least a quarterly 
basis. In addition, joint EMA and FDA meetings and workshops focused on the exchange of 
information on options available to drug developers have taken place on both sides of the Atlantic. 
 
                                                     
40http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf 
41 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm 
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Future: FDA and EMA will continue to hold regular meetings to discuss common issues in 
antibacterial drug development and regulation. 
 
Issue: Antibacterial drug developers need clear guidance on development of drugs 
w ith the potential to treat resistant bacterial infections 
Recommendation 17: Exchange information on possible approaches for developing drugs for 
bacterial diseases if limited drugs are available (i.e., bacterial diseases for which insufficient 
antibacterial drug therapies are available often due to AMR) 
− Implementers: FDA and EMA 
− Timeline: Within one year of adoption of recommendation 
 
FDA and EMA have exchanged information on possible approaches and each agency continues to 
update guidance documents on drug development programs for antibacterial drugs to address 
unmet medical needs. 
 
In November 2013, EMA published the final “Addendum on the note for guidance on the evaluation 
of medicinal products indicated for treatment of bacterial infections,”42 which includes 
recommendations on clinical trials and programs for development of antibacterial drugs for specific 
indications including for bacterial diseases for which there are limited therapeutic options for 
treating patients. 
 
In July 2013, FDA published the draft guidance “Guidance for Industry Antibacterial Therapies for 
Patients with Unmet Medical Need for the Treatment of Serious Bacterial Diseases”43. The public 
comment for this draft guidance closed in October 2013, and FDA is working to evaluate the input 
received before developing the final guidance document on this topic.  
 
In December 2013, members of the US Congress introduced legislation to establish a new 
development pathway for limited population antibacterial drugs (LPAD). LPAD drugs would be 
approved to treat limited populations of patients with serious or life-threatening manifestations of 
specific bacterial infections where few or no therapeutic options are available. The US 
Administration has not yet taken a position on the bill. However, FDA will work with Congress to 
provide technical assistance on legislation, as requested.  
 
                                                     
42http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129443.pdf 
43http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM359184.pdf 
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Future: FDA and EMA will continue to exchange information on possible approaches to developing 
drugs for patients for whom we have few therapeutic options. 
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Conclusions 
 
This report summarises the progress and the outcomes of the Transatlantic Taskforce on 
Antimicrobial resistance on the 17 recommendations that were identified to strengthen EU and US 
communication and cooperation in the area of AMR. 
 
While significant progress has been made in the areas of appropriate therapeutic use of 
antimicrobial drugs in human and veterinary medicine, prevention of drug resistant infections and 
strategies to improve development of new antibacterial drugs for use in human medicine, AMR 
continues to escalate. Therefore, the work of the TATFAR will continue for a period of at least two 
years. Major outcomes, such as consensus papers, meeting reports, and periodic progress reports, 
will be posted on the TATFAR website. 
 
Antimicrobial resistance is a growing and complex threat that requires sustained and coordinated 
action. Through the extension of the TATFAR mandate, the US and the EU reaffirm their 
commitment to working collaboratively through the TATFAR to address this priority public health 
issue. 
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Annex A: Abbreviations and acronyms 
 
AGISAR  WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance 
AMR   Antimicrobial resistance 
ANSE   French Agency for Food, Environmental and Occupational Health & Safety 
ARHAI  Antimicrobial Resistance and Healthcare-Associated Infections 
ARLG   Clinical Research Network on Antibacterial Resistance 
CDC   US Centers for Disease Control and Prevention 
CLSI   Clinical Laboratory Standards Institute 
CMVP   Committee for Medicinal Products for Veterinary Use 
DG RTD  European Commission‘s Directorate-General for Research and Innovation 
DG SANCO  European Commission‘s Directorate-General for Health and Consumers 
EC   European Commission 
ECDC   European Centre for Disease Prevention and Control 
ECOFFs  Epidemiological cut-off values 
EEA   European Economic Area 
EFSA   European Food Safety Authority 
EMA   European Medicines Agency 
ECCMID  European Congress of Clinical Microbiology and Infectious Diseases 
ESCMID  European Society of Clinical Microbiology and Infectious Diseases meeting 
ESVAC  European Surveillance of Veterinary Antimicrobial Consumption 
EU   European Union 
EUCAST  European Committee on Antimicrobial Susceptibility Testing 
FDA   US Food and Drug Administration  
GAIN   Generating Antibiotic Incentives Now Act 
HAI   Healthcare-associated infection 
HHS    US Department of Health and Human Services  
ICAAC  Interscience Conference on Antimicrobial Agents and Chemotherapy 
IMI   Innovative Medicines Initiative 
LPAD   Limited Population Antibacterial Drugs 
MDR   Multidrug-resistant 
MRSA   Methicillin-resistant Staphylococcus aureus  
NHSN   National Healthcare Safety Network 
NIH/NIAID US National Institutes of Health / National Institute of Allergy and Infectious 
Diseases 
LTCFs   European long-term care facilities 
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OIE   World Organisation for Animal Health 
PPS   Point prevalence survey  
SOP   Standard Operating Procedure 
TATFAR  Transatlantic Taskforce on Antimicrobial Resistance 
ToR   Term of References 
US   United States of America  
WHO   World Health Organization 
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Annex B: TATFAR members 
 
TATFAR members 
United States delegation 
HHS US Nils Daulaire 
HHS US Anne Yu 
CDC US Steve Solomon 
CDC US Jean Patel 
CDC US J. Todd Weber 
NIH/NIAID US Dennis Dixon 
NIH/NIAID US Jane Knisely 
FDA US Edward Cox 
FDA US Patrick McDermott 
European Union delegation 
EC – DG SANCO EU John Ryan  
EC – DG SANCO EU Paolo Guiglielmetti 
EC – DG RTD EU Line Matthiessen 
EMA EU David Mackay 
EFSA EU Ernesto Liebana 
ECDC EU Dominique L. Monnet 
EU Presidency trio representatives   
Ireland Eibhlín Connolly 
Lithuania Loreta Asokliene 
Greece Fofo Kaliva 
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Annex C: Scope and term of reference of TATFAR44 
 
Objectives and outcome  
The taskforce should increase the mutual understanding of US and EU activities and programmes 
relating to antimicrobial issues, deepen the transatlantic dialogue, provide opportunities to learn 
from each other, and promote information exchange, coordination, and cooperation between the 
US and the EU.  
The outcome of the taskforce efforts was a proposal with suggestions for areas of future 
collaboration between the EU and the US. The proposal was presented at the EU–US Summit in 
2011, leaving it for the political leaders to decide on which initiatives should be approved and 
prioritised for further cooperation.  
The challenges posed by AMR are well-documented and one more report describing the current 
situation and the risks posed by AMR would not be the best use of the taskforce‘s limited time and 
resources. Therefore, the taskforce will not duplicate what is being done in other fora. The 
outcome of the taskforce should be regarded exclusively as technical and scientific statements or 
suggestions and neither represent or impose a formal or binding position on the part of the US or 
the EU. 
 
Composition of the taskforce 
The taskforce and any related working groups shall be composed of members of the civil service 
for the EU and government officials for the US. The members shall have a general overview on 
health-related issues or a specific knowledge on AMR. The taskforce will consist of 18 members 
(up to nine from the US and up to nine from the EU) and the secretariat.  
 
The United States will be represented by the following agencies or offices of the Department of 
Health and Human Services: 
• Office of Global Affairs (OGA) 
• Centers for Disease Control and Prevention (CDC) 
• Food and Drug Administration (FDA) 
• National Institutes of Health, National Institute of Allergy and Infectious Diseases 
(NIH/NIAID) 
 
The European Union will be represented by the following agencies and organisations: 
- European Commission: 
• EC Directorate-General for Health and Consumers (two representatives) 
                                                     
44 Transatlantic Taskforce on Antimicrobial Resistance Report, 2011 
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• EC Directorate-General for Research 
• European Centre for Disease Prevention and Control (ECDC) 
• European Medicines Agency (EMA) 
• European Food Safety Authority (EFSA) 
 
- Council of the European Union, represented by the TRIO Presidency in order to keep the 
Council regularly informed of progress. 
 
Focus areas  
The work of the taskforce was guided by the focus areas defined by the 2009 EU–US Summit 
declaration "to establish a transatlantic taskforce on urgent AMR issues focused on appropriate 
therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of 
both healthcare- and community-associated drug-resistant infections, and strategies for improving 
the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation 
between us." 
 
TATFAR  
1. Appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities 
2. Prevention of drug-resistant infections 
3. Strategies for improving the pipeline of new antimicrobial drugs, diagnostic procedures, and 
techniques and maintaining existing drugs on the market 
 
The taskforce concluded its work by March 2011 and will continue beyond this timeframe after the 
consent of all parties.  
 
Operating procedures  
The taskforce was co-chaired by the US and the EU. The chairs were appointed by consensus. The 
ECDC provided the taskforce with a secretariat to deal with the administrative aspects of 
organising and running the day-to-day arrangements until 31 December 2013. 
The work was conducted in three distinct phases: (1) agreement between the EU and the US on 
the terms of reference; (2) identification of potential issues for cooperation; and (3) drafting and 
discussion of the final document. 
The taskforce held two face-to-face meetings. A kick-off meeting was held in the US in June 2010 
to agree on the terms of reference, a timeline, appointment of the chairs of the taskforce, and 
how to consult and involve third parties. A second face-to-face meeting was held in the EU in 
March 2011 to provide orientation to the final recommendations. 
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Consultation, external interaction, and workshops  
The US and EU partners of the taskforce sought, when appropriate, to obtain input from the 
public, interested experts, and other stakeholders, in accordance with each partner‘s respective 
process for obtaining public comment, on the specific activities within the framework of the 
Declaration where EU–US collaboration could be most fruitful. 
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Annex D: The TATFAR recommendations for future collaboration 
 
TATFAR recommendations for future collaboration 
Key Area I. Appropriate therapeutic use in human and veterinary medicine 
Opportunity for collaboration Recommendation 
Antimicrobial stewardship in human 
medicine 
1 Develop common structure and process indicators for hospital 
antimicrobial stewardship programmes 
Surveillance of antimicrobial use in 
human and veterinary communities 
2 Convene a joint EU/US working group to propose standards for measuring 
antimicrobial use in hospital settings 
3 Collaborate in collection of data on sales and use of veterinary 
antimicrobial drugs in food-producing animals 
Risk analysis on foodborne AMR 
 Collaborate on implementation of the Guidelines for Risk Analysis of 
Foodborne Antimicrobial Resistance prepared by Codex Alimentarius 
5 Enhance information sharing on approaches to promoting appropriate use 
in veterinary communities 
18 Establish a joint working group of international subject matter experts to 
identify key knowledge gaps in understanding the impact of antimicrobial 
use in animals on the risk to man from antimicrobial resistance  
Campaigns to promote appropriate 
use in human medicine 
6 Establish an EU–US working group to assess the evidence for 
effectiveness of communications tools in promoting behaviour change to 
increase appropriate use and to develop joint priorities 
Key Area II. Prevention of drug-resistant infections 
Surveillance of drug-resistant 
infections 
7 Consultation and collaboration on a point-prevalence survey for HAIs 
8 Develop a process for transatlantic communication of critical events that 
may signify new resistance trends with global public health implications 
9 Encourage efforts to harmonise, to the extent possible, interpretive 
criteria for susceptibility reporting of bacterial isolates across surveillance 
programmes in the US and EU 
Prevention strategies 
10 Convene a workshop bringing together public health experts from the US 
and EU to develop consensus evaluation tools for hospital infection 
control programmes 
11 Develop a transatlantic strategy to facilitate vaccine development for HAIs 
Key Area III. Strategies for improving the pipeline of new antimicrobial drugs 
Incentives to stimulate development 
of new antibacterial drugs in human 
medicine 
12 Policymakers should strongly consider establishing significant incentives 
to stimulate antibacterial drug development 
Research to support the 
development of new antibacterial 
drugs 
13 Increase communication between US and EU research agencies to 
identify common scientific challenges that may represent opportunities for 
collaboration   
14 Publicise funding opportunities to EU, US research communities 
Regulatory approaches for 
antibacterial products 
15 FDA and EMA will discuss ways to facilitate the use of the same clinical 
development programme to satisfy regulatory submissions to both 
Agencies 
16 Establish regular meetings between FDA and EMA to discuss common 
issues in antibacterial drug development and regulation 
17 Exchange information on possible approaches to drug development for 
bacterial diseases where limited drugs are available  
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Annex E: Timeline of the Transatlantic Task Force on Antimicrobial Resistance (TATFAR), 2009-2013
  
3 November 2009 
2009 EU-US Summit Declaration 
14 − 15 June 2010  
Face to face meeting, US 
1 October 2010  
US Public meeting 
17 November 2010  
EU web based stakeholder  
consultation 
23 − 24 March 2011  
Face to face meeting, EU 
3 December 2013  
Audio conference 
22 September 2011 
Recommendations for 
future collaboration 
between the US and EU 
May 2014 
TATFAR progress 
report 
2011-2013: 
Implementation of the 
recommendations 
2009 2010 2011 2012 2013 2014 2015 
2014-2015: 
Extension of TATFAR 
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Annex F: Ongoing activities: joint, EU, and US 
 
Note that this list of activities is not meant to be an exhaustive list of all activities undertaken by 
either the EU or the US to address AMR. The emphasis is on those major activities that could 
potentially provide opportunities to learn from each other, point to areas of future collaboration, or 
are either novel or highly successful projects. For more information on current activities to address 
the issue of antibacterial resistance, please see the respective websites of the relevant EU and US 
organisations and agencies. 
 
1. Appropriate therapeutic use of antibacterial drugs in the medical and veterinary 
communities 
  
 Ongoing activities addressing appropriate therapeutic use of antibacterial drugs in 
medical communities 
 
A. Measures to support appropriate therapeutic use (of antibacterial agents) in 
medical communities 
 
Antibacterial stewardship programmes 
 
Joint activities 
 
− Awareness campaigns on the prudent use of antibacterial agents in outpatient settings are 
supported in the US and the EU. The US campaign Get Smart: Know When Antibiotics Work 
is coordinated by CDC and the EU campaign European Antibiotic Awareness Day is 
coordinated by ECDC. CDC and ECDC are working closely to coordinate the campaigns. In 
2010, the US and EU agreed to match the timing of their campaign launches (US: week of 
18 November; EU: 18 November).  
 
EU activities 
 
− European Antibiotic Awareness Day is an annual European public health initiative that takes 
place on 18 November to raise awareness about the threat to public health of antibiotic 
resistance and prudent antibiotic use. The objective of the European Antibiotic Awareness 
Day in 2013 was to support efforts at national level to reduce unnecessary antibiotic use in 
hospitals and in the community through the development and dissemination of educational 
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materials promoting prudent antibiotic use. The motto for the European Antibiotic Awareness 
Day in 2013 is “Everyone is responsible.” 
 
− ABS (AntiBiotic Strategies) International was a project to implement strategies for 
appropriate use of antibiotic drugs in hospitals in Member States of the European Union. It 
was funded 2006–2008 and was a partnership of nine Member States of the EU: Austria, 
Belgium, Czech Republic, Italy, Germany, Hungary, Poland, Slovakia, and Slovenia. It 
developed training and guidance documents on strategies, organisation, and structure and 
process indicators for hospital antimicrobial stewardship programmes. 
 
− CHAMP (Changing behaviour of health care professionals and the general public towards a 
more prudent use of antimicrobial agents) is a project that summarised the available 
evidence and assessed expert opinions and views of professionals and patients on activities 
that target rational and cost-effective use of antibiotic drugs for the management of 
respiratory infections in primary care. Analyses of the cost-effectiveness of the different 
interventions that aim to improve antibiotic use have been performed. On the basis of the 
information that was gathered and analysed, a best-practice intervention has been 
developed. The project studied the implementation and feasibility of this best-practice 
intervention.  
  
− SATURN (Specific antibiotic therapies on the prevalence of human host resistant bacteria) is 
a project that studies the impact of antibiotic exposure on antibiotic resistance with a 
multidisciplinary approach that bridges molecular, epidemiologic, clinical, and 
pharmacological research. Many results drawn from previous studies of the effect of 
antibiotic use on emergence, selection, and spread of AMR have lacked a holistic view. As 
part of SATURN, clinical studies will be conducted including a randomised trial to resolve an 
issue of high controversy (antibiotic cycling vs. mixing) and three observational studies on 
the effect of antibiotic use on antibiotic resistance that are not easily assessable through 
randomised trials. 
 
− In June 2013, ECDC published an evidence-based guidance for healthcare professionals 
presenting five key perioperative antibiotic prophylaxis modalities for preventing surgical site 
infections, based on systematic review45. The document includes evidence-based guidance, 
structure, and process indicators as well as implementation toolkits, when appropriate. ECDC 
                                                     
45 http://ecdc.europa.eu/en/publications/Publications/Perioperative%20antibiotic%20prophylaxis%20-%20June%202013.pdf 
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is also preparing systematic reviews and evidence-based guidance on organisation of 
hospitals antimicrobial stewardship programmes.  
 
US activities 
 
− Get Smart for Healthcare is CDC campaign focused on improving in-patient antimicrobial use. 
The goal of Get Smart for Healthcare is to optimise the use of antimicrobial agents in in-
patient healthcare settings by focusing on strategies to help hospitals and other in-patient 
facilities implement interventions to improve antibiotic use. Interventions and programmes 
designed to improve antibiotic use are also referred to as “antimicrobial stewardship.” Some 
of the initial work of this effort includes: evaluating ways to improve the treatment of urinary 
tract infections, evaluating the epidemiology of in-patient antibiotic use, and pilot testing the 
implementation of a novel stewardship implementation framework using the “Change 
Package and Driver Diagram Methodology” in partnership with the Institute for Healthcare 
Improvement. Get Smart for Healthcare is currently targeted towards acute care hospitals 
and will expand to long-term care facilities.  
 
− Get Smart: Know When Antibiotics Work was launched by CDC as the National Campaign for 
Appropriate Antibiotic Use in the Community in 1995. In 2003, this programme was renamed 
Get Smart: Know When Antibiotics Work in conjunction with the launch of a national media 
campaign. This campaign aims to reduce the increase antibiotic resistance by promoting 
adherence to appropriate prescribing guidelines among providers, decreasing demand for 
antibiotic drugs for viral upper respiratory infections among healthy adults and parents of 
young children, and increasing adherence to prescribed antibiotic drugs for upper respiratory 
infections.  
 
Appropriate use of diagnostic tests  
 
EU activities 
 
− GRACE (Genomics to combat resistance against antibiotics in community-acquired lower 
respiratory tract infections in Europe) is a Network of Excellence focusing on community-
acquired lower respiratory tract infections (LRTI). The objective of GRACE is to integrate 
centres of research excellence and exploiting genomics in the investigation of community-
acquired LRTI. Microbial and human genomics are being integrated with health sciences 
research consisting of clinical observational and intervention studies, health economics, and 
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health education to change practice in managing community-acquired LRTI. GRACE 
organised professional education, including web-based teaching and practical courses. 
GRACE created a genomic laboratory network in eight European countries and a primary care 
research network in 11 European countries. The consortium will become a virtual "European 
LRTI Research Centre," potentially leading to a forum promoting research and good practice 
in the field of community-acquired LRTI. 
 
− Health alliance for prudent prescribing, yield and use of antimicrobial drugs in the treatment 
of respiratory tract infections (HAPPY AUDIT) is a project on respiratory tract infections in 
general practice. The objective of the project is to improve the quality of diagnostic 
procedures and treatment of respiratory tract infections in order to ensure that patients get 
only necessary antibiotic drugs. The project expects to be able to reduce the total antibiotic 
prescribing rate to help avoid development of resistance. It developed intervention 
programmes targeting general practitioners (GPs), parents of young children and healthy 
adults, including guidelines, courses for GPs, workshops, and patient information leaflets for 
improving the quality of antibiotic prescription.  
 
US activities 
 
− CDC is collaborating with the Infectious Diseases Society of America to update practice 
guidelines for the diagnosis and management of group A streptococcal pharyngitis. In 
addition, CDC worked with an expert panel and the American Academy of Pediatrics to 
update the Principles of Judicious Use of Antimicrobial Agents for Pediatric Upper Respiratory 
Tract Infections46. 
 
Product labelling and literature  
 
Joint activities 
 
− The FDA and the EMA each have staff assigned to work in the other agency, allowing candid, 
rapid, and confidential exchange of information regarding practices and policies that affect 
product labelling and other regulatory issues. 
 
EU activities 
                                                     
46 Hersh AL, Jackson MA, Hicks LA,  American Academy of Pediatrics Committee on Infectious Diseases. Principles of judicious antibiotic prescribing for 
upper respiratory tract infections in pediatrics. Pediatrics. 2013 Dec;132(6):1146-54. 
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− Paediatric Regulation: New legislation governing the development and authorisation of 
medicines for use in children aged 0 –17 years was introduced in the European Union in 
January 2007. The new piece of legislation – Regulation (EC) No 1901/2006 as amended – 
introduces sweeping changes into the regulatory environment for paediatric medicines, 
designed to better protect the health of children in the EU.  
The Paediatric Regulation also brings in many new tasks and responsibilities for the EMA, 
chief of which is the creation and operation of a Paediatric Committee within the Agency to 
provide objective scientific opinions on any development plan for medicines for use in 
children. Medicines are used in children despite a relative lack of information on how to 
prescribe safely. This is called off-label use. The Paediatric Regulation aims to improve the 
information available to prescribers and families and therefore to reduce off-label use.  
In June 2013, the European Commission published a report on the first five years of the 
regulation. The report concludes that paediatric development has become a more integral 
part of the overall development of medicinal products in the EU, with the Regulation working 
as a major catalyst to improve the situation for young patients. It also identifies some areas 
for improvement, such as the low uptake of the paediatric-use marketing authorisation 
(PUMA) by companies, which the Agency, together with the European Commission, intends 
to address during its fine-tuning of the current implementation of the regulation. 
 
US activities 
 
− FDA has had labelling regulations addressing the appropriate use of antibacterial drugs for 
use in humans since 2003 (21 CFR Part 201.24). Antibacterial labelling regulations 
addressing the proper use of antibiotics since 2003 (21 CFR Part 201). Labelling for antibiotic 
drugs contains required statements that antibacterial drugs should be used only to treat 
patients with infections that are proven or strongly suspected to be caused by bacteria and 
also encourages healthcare professionals to counsel patients about proper use of 
antibacterial drugs. 
 
B. Surveillance of use of antibacterial agents in medical communities  
 
EU activities 
 
− The European Surveillance of Antimicrobial Consumption Network (ESAC-Net), previously 
known as the European Surveillance of Antimicrobial Consumption project (ESAC), is a 
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Europe-wide network of national surveillance systems coordinated by ECDC that provides 
European reference data on antimicrobial drug use. All 28 EU Member States are reporting 
data on the use of drugs to treat infections caused by bacteria (antibacterial drugs), viruses 
(antivirals), and fungi (antimycotics). 
 
− ARPEC (Antibiotic resistance and prescribing in European children) is a network that will 
develop a prospective surveillance system to monitor rates of prescribing antibiotic drugs and 
resistance in EU children. This surveillance will be used to determine the variation in choice 
of drug, dose, and indications for prescribing antibiotic drugs for common childhood 
infections in the community and hospitals between EU countries. ARPEC will propose a novel 
paediatric defined daily dose (DDD) method for comparison of hospital-based antibiotic 
prescribing for children (current DDD guidelines are based on adult dosage). Other activities 
will include a prevalence survey to compare antibiotic use in children in hospitals, setting 
early benchmarks for prescribing and resistance rates and working with clinical experts of the 
European Society for Paediatric Infectious Diseases (ESPID) to implement the benchmarks 
and encourage the development of prudent and more unified EU-wide treatment guidelines. 
 
− APRES (Appropriateness of prescribing antibiotics in primary healthcare in Europe with 
respect to antibiotic resistance) is a project that investigates the appropriateness of 
prescribing antibiotic drugs in primary healthcare facilities. In nine European countries data 
are being collected on antibiotic drug resistance patterns of bacteria circulating in the 
community. This data will be compared with antibiotic drug prescribing patterns retrieved 
from primary care practices in an analysis to determine the relationship between the 
antibiotic resistance pattern for bacteria and the pattern of antibiotic prescription behaviour. 
 
− Self-medication with antimicrobial drugs in Europe (SAR) is a project that recruited European 
countries from two networks of surveillance systems: ESAC and EARSS. The project’s goal 
was to compare the prevalence of antimicrobial drug self-medication in the previous 12 
months and intended self-medication and storage and to identify the associated demographic 
characteristics.  
 
− In 2011–2012, ECDC conducted the first EU-wide point prevalence survey (PPS) of HAIs and 
antimicrobial drug use in acute care hospitals in 30 EU/EEA Member States. An estimated 
2800 healthcare workers from 1200 hospitals across Europe were trained by national PPS 
coordinating staff to implement the standardised PPS methodology. Data from a total of 273 
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753 patients in 1149 hospitals were submitted to ECDC in order to estimate the prevalence 
of healthcare-associated infections in European hospitals. 
 
− HALT-2 (Healthcare-associated infections in long-term care facilities) is a project funded by 
ECDC to extend the control of healthcare-associated infections and AMR in European long-
term care facilities (LTCFs) by performing repeated point prevalence surveys on healthcare-
associated infections, AMR, antibiotic use, current infection control, and antimicrobial 
stewardship practices and resources in all 28 EU Member States, 3 EEA/EFTA, and 2 EU 
enlargement countries. This project builds on the results of a previous ECDC-funded project 
(2009-2011) that aimed to develop and implement a protocol for surveillance of HAI, 
antimicrobial use, and resistance in European LTCFs in order to establish baseline rates and 
identify priorities for improvement. 
 
US activities 
 
− The National Healthcare Safety Network (NHSN) is a voluntary, secure, internet-based 
surveillance system that integrates patient and healthcare personnel safety surveillance 
systems managed by the Division of Healthcare Quality Promotion (DHQP) at CDC. 
Enrolment in NHSN is open to all types of healthcare facilities in the US, including acute care 
hospitals, long-term acute care hospitals, psychiatric hospitals, rehabilitation hospitals, 
outpatient dialysis centres, ambulatory surgery centres, and long-term care facilities. In 
2011, CDC launched a new version of the Antibiotic Use Module of the NHSN that permits 
electronic reporting of antimicrobial drug use data from healthcare facilities.  
 
− CDC’s National Ambulatory Medical Care Survey (NAMCS) provides data on antibiotic 
prescribing by condition. NAMCS is a national survey designed to collect objective, reliable 
information about the provision and use of ambulatory medical care services in the US. 
Findings are based on a sample of visits to non-federal, office-based physicians who are 
primarily engaged in direct patient care. In addition, CDC currently is in the process of 
gaining access to proprietary antibacterial use data that may allow for comparisons in 
antimicrobial use rates and trends between countries.  
 
− CDC and the 10-state Emerging Infections Program (EIP) launched a healthcare-associated 
infection and antimicrobial use point prevalence survey in 2011 that was conducted in 
general, acute-care hospitals in the 10 EIP states. The 2011 survey yielded information on 
the burden and types of healthcare-associated infections affecting patients hospital-wide, as 
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well as the frequency and types of antimicrobial drugs being administered to patients and 
the rationale for their use. 
 
C. Promotion of training of health professionals in medical communities 
 
EU activities 
 
− Prior to conducting the EU-wide PPS of HAIs and antimicrobial use in acute care hospitals47, 
ECDC developed a standardised methodology, training materials, a “train-the-trainer” 
course for national PPS coordinating staff, free hospital software for data collection, and a 
validation methodology. The ECDC PPS and the national PPS coordinating team trained 
approximately 2800 hospital staff. 
US activities 
 
− CDC supported the development of web-based medical school curriculum on appropriate 
antibiotic drug use on the basis of curriculum that has been pilot tested at several medical 
schools. The curriculum was launched online in 2013. The curriculum is intended for third- 
and fourth-year medical students. 
 
− CDC’s Get Smart: Know When Antibiotics Work programme developed a continuing education 
programme and new web content to train community pharmacists to incorporate appropriate 
antibiotic use education into practice. Educational materials and guidelines for healthcare 
providers are available online. Additional guidelines are in development. 
 
− The Get Smart for Healthcare program is planning a number of training/educational 
opportunities for healthcare professionals, including: a CME programme at the annual IDSA 
meeting on antimicrobial stewardship (co-sponsored by SHEA/IDSA) and an online CME 
programme on antimicrobial stewardship for community hospitals. The Get Smart for 
Healthcare Website will also feature a variety of training and educational materials. 
 
D. Information/education campaigns in medical communities  
 
Joint activities 
 
                                                     
47 http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf 
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− In 2013, ECDC and CDC, with partner agencies in Canada and Australia published a joint 
editorial entitled “Global collaboration essential to spread the message on prudent antibiotic 
use”48 on prudent antibiotic use campaigns in the US and EU, as well as in Canada and 
Australia in Lancet Infectious Diseases. 
 
EU activities  
 
− Full issue of Eurosurveillance dedicated to the topic of AMR was published in coordination 
with European Antibiotic Awareness Day 2010 with articles from ECDC, France, the 
Netherlands, and multinational groups. 
 
− ECDC funded the development of a pilot e-learning module for continuous medical education 
on use of antibiotic drugs in hospitals by the Dutch Working Party on Antibiotic Policy 
(Stichting Werkgroep Antibiotica Beleid – SWAB). This module consists of a series of 
questions and provides immediate feedback to answers with the objectives of improving 
knowledge, attitudes, and behaviour on principles of prudent antibiotic use, including 
antibiotic stewardship strategies. In the future, the module will be used to evaluate the 
impact of information/education campaigns on prudent antibiotic use on hospital prescribers. 
 
− e-Bug is a European-wide antibiotic and hygiene teaching resource for junior and senior 
school children. This resource not only reinforces an awareness of the benefits of antibiotic 
drugs but also teaches prudent antibiotic use and how inappropriate use can have an 
adverse effect on an person’s good microbes and antibiotic drug resistance in the community. 
The project is led by the Public Health England (PHE) Primary Care Unit in UK, and involves a 
consortium of 24 partner EU/EAA countries and 3 non-EU countries. Project development 
was 60% funded by DG SANCO. Since 2010, the website has been supported by PHE in 
England. ECDC supported translation of all the resources into the other European languages. 
 
− ECDC developed a toolkit of template materials for national health authorities to adapt and 
use as part of national campaigns on appropriate antibiotic drug use for hospital prescribers. 
Endeavours to help intervention planners understand, shape, and develop effective 
communication strategies and tactics come under the rubric of formative evaluation. 
Formative evaluation of the toolkit has been undertaken through research with stakeholder 
groups with the aim of developing consensus on the toolkit components. This formative 
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evaluation had two stages: a questionnaire survey followed by a consensus building exercise. 
A report on the consensus building exercise is available. 
 
 Ongoing activities addressing appropriate therapeutic use of antibacterial drugs in 
veterinary communities 
 
A. Measures to support appropriate therapeutic use (of antibacterial agents) in 
veterinary communities 
 
Antibacterial stewardship programmes 
 
Joint activities 
 
− WHO Advisory Group on Integrated Surveillance on Antimicrobial Resistance (AGISAR)  
 
− Other international activities in which the US and the EU have participated 
• Codex Alimentarius ad hoc Intergovernmental Taskforce on AMR 
• OIE Terrestrial Animal Health Code and Aquatic Animal Health Code 
• Reports of the FAO/WHO/OIE Expert meetings on critically important antimicrobials; 
• Codex Code of Practice to Minimize and Contain Antimicrobial Resistance 
 
EU activities  
 
− The EU has adopted the following initiatives: 
 
The Communication of 15 November 2011 from the Commission to the European Parliament 
and the Council - Action Plan against the rising threats from Antimicrobial Resistance. The 
European Commission proposes to put in place a five-year action plan to fight against AMR 
based on 12 key actions49. The Commission has published a road map on the implementation 
of the 5 years action plan50 and convened a conference in December 2013 as part of a mid-
term review of the implementation of the Action Plan. 
 
The Council of the European Union has adopted several conclusions related to AMR and use of 
antimicrobial drugs in veterinary medicine. For example, the Council conclusions of 22 
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June 2012 on the impact of AMR in the human health sector and in the veterinary sector – 
a "One Health" perspective51. 
During its plenary sitting of 11 December 2012, the European Parliament adopted a Report on 
the Microbial Challenge – Rising threats from Antimicrobial Resistance (2012/2041 (INI)) – 
adopted 11 December 201252. 
 
The European Parliament adopted a resolution on antibiotic resistance on 12 May 2011 and a 
resolution on the public health threat of AMR on 27 October 2011. 
 
Also the following provisions and legislative proposals are in place  
• Marketing authorisation requirements, antimicrobial drugs prescription-only 
medicines (Veterinary Medicines Directive 2001/82/EC); 
• New legislation on monitoring and reporting of AMR in Salmonella, Campylobacter, 
and indicator commensal E. coli and Enterococcus spp. Commission Implementing 
Decision 2013/652/EU on the monitoring and reporting of antimicrobial resistance in 
zoonotic and commensal bacteria53 54.; 
• Ban on the use antimicrobial drugs for Salmonella eradication in poultry 
(Commission Regulation 1177/2006). 
 
− Research related to animal health, biosecurity on farms, vaccines, bacteriophages, breeding 
of more robust or disease resistant animals, substitutes to antimicrobial growth promoters. 
 
− As an example, the following activities have been undertaken by different EU Member States: 
• Animal healthcare programmes/agreement systems. They aim to improve 
veterinary-farmer cooperation, animal health and welfare and prudent use of 
medicines 
• Recommendations and prudent use guidelines on antimicrobial use on 
species/indication/dosage level, recommendations on preventing MRSA infections in 
animals 
• Restrictions on off-label use, ban of the use of human last resort antimicrobial drugs 
• Specific requirements for pre-treatment susceptibility testing for group treatments 
• Strategic programmes involving human and veterinary medicine, joint AMR 
surveillance 
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• A special attention to 3rd and 4th generation cephalosporins, fluoroquinolones, and 
macrolides; at national level special requirements or restrictions 
• Enforcement measures (veterinarians and farmers) 
 
The EMA has published recommendations on use and authorisation of quinolones for 
animals55, and third- and forth-generation cephalosporins56, macrolides57, colistin58, 
glycylcyclines,59 and pleuromutilins60. 
 
US activities 
 
− The FDA and the American Veterinary Medical Association (AVMA) developed outreach 
materials on judicious use targeted to food animal producers. These consist of a series of 
booklets that explain antimicrobial prudent use principles in depth for beef cattle, dairy 
cattle, swine, poultry, and aquatic veterinarians. See http://www.avma.org/issues/default.asp 
then continue down page to find each species. 
 
− FDA awarded a contract to develop a web-based decision support system for use by 
veterinarians to select and use antimicrobial agents appropriately. The Veterinary 
Antimicrobial Decision Support (VADS) system continues to be revised and improved.  
 
− The US Interagency Task Force on Antimicrobial Resistance and Public Health Action Plan to 
Combat Antimicrobial Resistance was created in 1999 to develop a national plan to combat 
AMR. It is co-chaired by FDA, CDC, and NIH/NIAID. Agencies report annually on progress. 
The taskforce also includes the Agency for Healthcare Research and Quality, Centers for 
Medicare and Medicaid Services, Health Resources and Services Administration, United States 
Department of Agriculture (USDA), Department of Defense, Department of Veterans Affairs, 
and the Environmental Protection Agency. In 2001, the US Agency for International 
Development joined the taskforce to help address global AMR issues. 
 
− The One Health approach to the health and well-being of all species has been endorsed by 
the US agencies participating in TATFAR and offers many promising avenues of collaboration 
between the US and the EU61 62. 
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− NARMS, established in 1996, continually monitors AMR among enteric bacteria (e.g., 
Salmonella, Campylobacter, E. coli, Enterococcus) in animals presenting for slaughter, 
animals on farm, humans, and retail meat. Animals include cattle, swine, chickens and 
turkeys; retail meat includes beef, pork and poultry.  
 
Appropriate use of diagnostic tests  
 
Joint activities 
 
− Both the EU and the US participate in the Codex Taskforce on Antimicrobial Resistance, 
which promotes the use of and improving availability, speed, and accuracy of diagnostic 
microbiological tests. 
 
EU activities  
 
− EU reference laboratory and national reference laboratories in each Member State for AMR 
were established 2006. The EU-RL aims to develop and distribute methods for resistance 
analyses and to provide training and assistance to national reference laboratories. 
 
− In some EU Member States, certain antimicrobial drugs (e.g. fluoroquinolones) cannot be 
used unless a recent diagnostic test reveals that no other antimicrobial drug is effective for 
that disease in that specific herd. Appropriate diagnostic testing is controlled and compared 
to the treatment guidelines. In some Member States, microbiologic diagnosis is required 
before group medications can take place. 
 
US activities 
 
− Antimicrobial resistance testing method development and training is done in conjunction with 
NARMS. 
 
− FDA and CDC participate in the Clinical Laboratory Standards Institute (CLSI), Veterinary 
Subcommittee. 
 
Product labelling and literature  
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Joint activities 
 
− Both the EU and the US participate in the Codex Taskforce on Antimicrobial Resistance, 
which has addressed product labelling and literature as an important aspect on controlling 
AMR.  
 
EU activities  
 
− European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) has 
guidelines on the Summary of Product Characteristics (SPC) for antimicrobial products, which 
takes into account how AMR has developed in recent years and provides detailed guidance 
on responsible use of antimicrobial drugs.  
 
− CVMP has developed reflection papers on the use of fluoroquinolones, third- and fourth-
generation cephalosporins, macrolides, pleuromutilins, and colistin in food producing 
animals. These papers contain recommendations regarding prudent use to be included in the 
summary of product characteristics (SPCs) for such products. The CVMP has been using 
referrals as a legal tool to implement prudent use warnings on the SPC of some antimicrobial 
drugs (e.g., (fluoro) quinolones or third- and fourth-generation cephalosporins). 
 
− A draft guideline for the demonstration of efficacy for veterinary medicinal products 
containing antimicrobial substances is currently under consultation. The guideline provides 
recommendations for the design and conduct of pre-clinical and clinical studies to support 
clinical efficacy for an antimicrobial veterinary medicinal product. 
 
US activities 
 
− FDA Guidance for Industry #152, Evaluating the Safety of Antimicrobial New Animal Drugs 
with Regard to Their Microbiological Effects on Bacteria of Human Health Concern, provides a 
pre-approval mechanism to evaluate the safety of antimicrobial animal drugs with regard to 
their microbiologic effects on bacteria of human health concern. Guidelines lay out a 
qualitative risk assessment approach to new animal antimicrobial drugs and apply risk 
management strategies to minimise any impact on human health.  
 
− FDA has produced several quantitative risk assessments on the issue of antimicrobial 
resistant bacteria in animals because of the use of antimicrobial drugs in animals transferring 
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to humans and causing antimicrobial-resistant infections, e.g., fluoroquinolone-resistant 
Campylobacter in poultry, macrolide resistance, and others. For qualitative risk assessments, 
see Guidance for Industry #152, above. 
 
− FDA Guidance for Industry #209, The Judicious Use of Medically Important Antimicrobial 
Drugs in Food-Producing Animals, published 13 April 2012, summarises some of the key 
scientific reports on the use of antimicrobial drugs in animal agriculture. It outlines FDA’s 
current thinking on strategies for ensuring that medically important antimicrobial drugs are 
used judiciously in food-producing animals in order to help minimise AMR development.  
 
Addressing inappropriate off-label use 
 
EU activities  
 
− In the EU, no maximum residue limits for cephalosporins are established for poultry, as a 
result cephalosporins cannot be used routinely in poultry and can only be used as an 
exception and “off-label’’ under the control a prescribing veterinary surgeon. Such use, 
therefore, does not cover routine in ovo injection or treatment of 1-day-old chicks. EMA has 
reinforced that cephalosporins should not be used in poultry, including in all SPCs for third- 
and fourth-generation cephalosporins a specific prohibition of off-label use, using the phrase 
“Do not use in poultry.” The specific recommendations on these classes of cephalosporins 
can be found as part of the report on the referral from the European Commission to the EMA 
under Article 35 of Directive 2001/82/EC, which encompassed all veterinary medicinal 
products containing systemically administered (parenteral and oral) third- and fourth-
generation cephalosporins intended for use in food-producing species. 
 
− Regarding AMR linked to the use of antimicrobial agents in companion animals, the CVMP 
has published a reflection paper on the risk of AMR transfer from companion animals63. 
Although this document does not directly address the off-label use in companion animals this 
subject is currently under discussion and is likely to be the subject of a reflection paper. In 
addition, EMA has received a request from the European Commission for advice on what the 
possible impact could be on the treatment of resistant bacteria in humans of granting 
marketing authorisations for new classes of veterinary antibiotic drugs, and whether the use 
of certain new classes of antimicrobial drugs or antibiotic substances (especially those that 
are important in human medicine) that are currently not authorized needs to be restricted in 
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animals. When answering this request, the EMA will take into account the off-label use of 
antibiotic drugs in animals.  
 
− In some EU Member States, there are restrictions or bans on off-label use and restrictions on 
the use of certain antimicrobial drugs that are critical for use in humans for all animal 
species. 
 
US activities 
 
− The FDA prohibits the extra-label use of certain antimicrobial drugs in food-producing 
animals because of the threat of public health harm, including fluoroquinolones and 
glycopeptides.  
 
− The FDA rescinded the approval of fluoroquinolones for use in poultry, effective September 
2005. Also see 1c.2. for additional regulatory actions.  
 
Over-the-counter sales 
 
EU activities  
 
− In the EU, all veterinary antimicrobial drugs are prescription-only medicines. 
 
US activities  
 
− FDA issued the 2012 final Guidance to Industry #209 announcing plans to limit medically 
important antimicrobial drugs in food-producing animals to those uses that have veterinary 
oversight or consultation. This would be prescription status or status similar to prescription 
for in-feed use (Veterinary Feed Directive).  
− In 2013 FDA issued final Guidance for Industry #213, which began the three-year timeframe 
to implement the plan announced in 2012. 
 
B. Surveillance of use of antibacterial agents in veterinary communities  
 
EU activities  
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− The European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) project, 
coordinated by the European Medicines Agency, started in 2009. It aims to collect data 
generated from surveillance of the sales of antimicrobial agents for use in animals to identify 
and quantify risk factors for the potential development and spread of AMR in animals. In 
October 2013, the Agency published its third report on sales of veterinary antimicrobial drugs 
from the ESVAC project64. A total of 25 EU and EEA countries submitted data on 2011 sales 
to the Agency. The 2013 report, as well as the reports from 2012 and 2011, will be used by 
risk assessors and risk managers in the European Commission and Member States to inform 
antimicrobial policy and the responsible use of antimicrobial drugs. 
 
− The ESVAC project has recently revised its reflection paper on collecting data on the use of 
antimicrobial agents by animal species65, on technical units of measurement, and indicators 
for reporting use of antimicrobial agents in animals. This document discusses how to 
establish systems for collecting reliable and standardised data on the use of antimicrobial 
agents by animal species for the ESVAC database and how to report the data taking into 
account the differences in dosing between the various antimicrobial agents as well as the 
animal population at risk for treatment. 
 
− Member States provide the necessary data on the use of antimicrobial drugs and on AMR in 
humans, animals, and food in the EU. A common analysis by the three agencies, EFSA, EMA, 
and ECDC, of these data, with joint conclusions on the occurrence of AMR in humans, 
animals, and food should result in a joint report of the three agencies, with harmonised and 
transparent presentation of the data. The first ECDC/EFSA/EMA joint report on the analysis of 
the relationship between the use of antimicrobial agents and occurrence of AMR in the 
human and animal sector will be produced in 2014. 
 
US activities  
 
− FDA is implementing Section 105 of the Animal Drug User Fee Amendments of 2008 to 
collect and publish animal antimicrobial drug distribution data.  
− In 2012, FDA solicited broad public comment on enhancements to the existing requirements 
related to the reporting of antimicrobial drug sales/distribution data, as well as input on 
alternative methods for monitoring antimicrobial use in food-producing animals.  
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− In September 2013 FDA sought additional public input on a new proposed format for the 
annual summary and expects to use the enhanced format when it summarizes the data 
reported for 2012.  
 
C. Promotion of training of health professionals in veterinary communities  
 
EU activities  
 
− Some EU Member States have animal healthcare programmes that include extensive training 
for veterinarians and farmers and audits. Audits can be seen as training for veterinarians. 
 
− Some EU Member States have established national cooperation bodies involving veterinary 
practitioners from different areas, as well as human health experts and competent 
authorities.  
 
− Some Member States organise education of veterinarians, farmers and other owners of 
animals. 
 
US activities 
 
− FDA awarded a contract to develop a web-based decision support system to be used by 
veterinarians to select and use antimicrobial agents appropriately. The Veterinary 
Antimicrobial Decision Support (VADS) System continues to be revised and improved. 
 
− FDA produced a nine-minute animation explaining to veterinarians how AMR both emerges 
and proliferates among bacteria.  
 
− FDA produced several videos and accompanying booklets on the prudent use of antimicrobial 
drugs.  
 
− Through the Get Smart on the Farm programme, CDC awarded funds to Michigan State 
University to develop an interactive web-based educational programme aimed at teaching 
and promoting the prudent use of antimicrobial agents in veterinary medicine, The 
Antimicrobial Resistance Learning Site for Veterinary Students. 
 
D. Information/education campaigns in veterinary communities  
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EU activities  
 
− European Antibiotics Awareness Day is used by many EU Member States as an opportunity to 
organise information campaigns on AMR and prudent use of antimicrobial drugs at national 
level also for veterinary medicine. 
 
− EPRUMA is a multi-stakeholder platform that links best practice with animal health and public 
health. It aims to promote the responsible use of medicines in animals in the EU. 
 
US activities 
 
The FDA and the American Veterinary Medical Association (AVMA) developed outreach materials 
on the judicious use of antimicrobial drugs that was targeted to food animal producers. These 
materials consist of a series of booklets that explain antimicrobial prudent use principles in depth 
for beef cattle, dairy cattle, swine, poultry, and aquatic veterinarians. See 
http://www.avma.org/issues/default.asp then continue down page to find each species. 
 
2. Prevention of drug-resistant infections 
 
A. Ongoing activities – Surveillance 
 
Joint activities 
 
− Point prevalence surveys of antimicrobial use and HAIs. Since 2009, CDC and ECDC worked 
together in attempts to harmonise key methods related to both ECDC and US PPS. 
Furthermore, in the planning phase of a pilot prevalence survey of HAIs and antimicrobial 
use in nursing homes, CDC is currently working with EU investigators to use a similar 
methodology for the US survey as that used for the ECDC-funded Healthcare-Associated 
Infections in Long-Term Care Facilities (HALT) project. 
 
EU activities 
  
− The European Antimicrobial Resistance Surveillance Network (EARS-Net), previously known 
as the European Antimicrobial Resistance Surveillance System (EARSS), is a European-wide 
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network of national surveillance systems providing European reference data on AMR for 
public health. It is coordinated by ECDC.  
− The European Surveillance of Antimicrobial Consumption Network (ESAC-Net), previously 
known as formerly the European Surveillance of Antimicrobial Consumption project (ESAC), is 
a Europe-wide network of national surveillance systems, providing European reference data 
on antimicrobial drug use. It is coordinated by ECDC. 
− The Healthcare-Associated Infections Network (HAI-Net) is the European network for the 
surveillance of HAIs. It is coordinated by ECDC and is largely based on the experience and 
activities of former networks financed by DG SANCO of the European Commission, namely 
Hospitals in Europe Link for Infection Control through Surveillance and Improving Patient 
Safety in Europe. 
 
− DebugIT (Detecting and Eliminating Bacteria UsinG Information Technology) is a project 
financed by the Directorate-General Information Society of the European Commission. It will 
use clinical and operational information from clinical information systems across the 
European Union and data mining techniques to monitor and provide decision support to 
prevent harmful patient safety events, including AMR. The benefits of this approach in terms 
of clinical and socio-economic outcomes will be measured. 
 
− TROCAR (Translational Research On Combating Antimicrobial Resistance) is a project that 
focuses on defining the major high-risk resistant clones, exploring genomic and proteomic 
approaches to investigate specific traits of epidemic clones, and developing bioinformatics 
tools to exploit genomics data. By combining the outputs of the project, TROCAR aims to 
provide the scientific basis for an early warning system when isolates of a particular 
epidemicity appear in the community and in hospitals. 
 
− For the veterinarian sector, EFSA is performing the surveillance of antimicrobial surveillance. 
EFSA recently published several scientific reports with recommendations on harmonised 
monitoring, analysis, and reporting of data: 
• Technical specifications on harmonised monitoring and reporting of AMR in Salmonella, 
Campylobacter, and indicator E. coli and Enterococci bacteria transmitted through food 
(June 2012)66 
• Technical specifications on harmonised monitoring and reporting of AMR in MRSA in food-
producing animals and food (October 2012)67 
                                                     
66 http://www.efsa.europa.eu/en/efsajournal/doc/2742.pdf 
67 http://www.efsa.europa.eu/en/efsajournal/doc/2897.pdf 
66 
 
• Technical specifications for the analysis and reporting of data on AMR in the EU Summary 
Report (February 2012)68 
• The EU Summary Report on AMR in zoonotic and indicator bacteria from humans, animals 
and food in 2011 (2013)69. 
 
− Upon a request from DG SANCO to review and harmonised the surveillance systems on AMR 
in the EU, EFSA published a scientific report that revised the existing technical specifications 
on the monitoring and reporting of AMR in the food chain. This report, as well as other 
scientific opinions of EFSA, is the basis of the newly reviewed EU legislation on AMR in the 
food chain. The new legislation (Decision 2013/652/EU) lays down the requirements for the 
harmonised monitoring of the most relevant, from a public health perspective, combinations 
of bacterial species/food producing animal populations/food and includes detailed rules for 
sampling, analysis of the isolates, and interpretations of the results. The legislation also 
includes the requirements for the harmonised monitoring and reporting of ESBL-, AmpC, and 
carbapenemase-producing bacteria in certain animal populations and in certain food types70. 
 
US activities 
 
− Active Bacterial Core Surveillance: Active laboratory- and population-based surveillance 
system for invasive bacterial pathogens of public health importance, including Haemophilus 
influenzae, Neisseria meningitidis, group A Streptococcus, group B Streptococcus, 
Streptococcus pneumonia, and MRSA. ABCs also provides an infrastructure for further public 
health research, including special studies aimed at identifying risk factors for disease, post-
licensure evaluation of vaccine efficacy, and monitoring effectiveness of prevention policies. 
ABCs reaches about 42 million people and operates in 10 EIP sites around the US.  
 
− Healthcare Associated Infections-Community Interface (HAIC) projects within the EIP: Active 
population-based surveillance for Clostridium difficile infection and other healthcare-
associated infections caused by pathogens such as Candida and multidrug-resistant gram-
negative bacteria. Sites also performed the 2011 acute care hospital HAI and antimicrobial 
use prevalence survey and performed time-limited projects evaluating innovations in HAI 
surveillance methods. 
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− Surveillance for healthcare-associated infections using NHSN: For a description of NHSN, see 
I.1.b.7. CDC measures HAIs and AMR associated with these infections in NHSN. In 
aggregate, CDC analyses and publishes surveillance data to estimate and characterise the 
national burden of HAIs. At the local level, the data analysis features of NHSN that are 
available to participating facilities range from rate tables and graphs to statistical analysis 
that compares the healthcare facility’s rates with the national aggregate metrics. 
 
− CLSI, in collaboration with EUCAST, held a workshop on 12 January 2013 CLSI to discuss the 
science of setting ECOFFs. Scientific principles outlined in this workshop will serve as a 
foundation for establishing harmonized ECOFFs in the future.  
 
B. Ongoing Activities – Prevention 
 
EU activities 
  
− ABS (AntiBiotic Strategies) International was a project to implement strategies for 
appropriate use of antibiotic drugs in hospitals in EU Member States. It was funded 2006–
2008 and was a partnership of nine EU Member States: Austria, Belgium, Czech Republic, 
Italy, Germany, Hungary, Poland, Slovakia, and Slovenia. It developed training and guidance 
documents on strategies, organisation, and structure and process indicators for hospital 
antimicrobial stewardship programmes. 
 
− In June 2013, ECDC published an evidence-based guidance for healthcare professionals 
presenting five key perioperative antibiotic prophylaxis modalities for preventing surgical site 
infections on the basis of systematic review71. The document includes evidence-based 
guidance, structure and process indicators, as well as implementation toolkits, when 
appropriate. ECDC systematic review and evidence-based guidance on organisation of 
hospital infection control programmes is expected to be published in December 2014. 
 
− IMPLEMENT (Implementing strategic bundles for infection prevention and management) is a 
project that aims to identify current national and local implementation strategies for 
preventing and managing central venous line infections and ventilator-associated pneumonia 
as well as for antimicrobial chemotherapy. IMPLEMENT will develop and test an optimal 
strategy for the implementation of bundles for infection prevention and management. 
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− PROHIBIT (Prevention of hospital infections by intervention and training) is a project that 
aims to understand existing guidelines and practices to prevent HAIs in European hospitals, 
to identify factors that enable and reduce compliance with best practices, and to test the 
effectiveness of interventions of known efficacy. PROHIBIT will develop recommendations for 
the EU, policy makers, managers, and medical professionals. 
 
− MOSAR (Mastering hOSpital Antimicrobial Resistance and its spread into the community) is a 
network that integrates and coordinates multidisciplinary prevention and control activities of 
16 hospitals in 9 European countries. In particular, MOSAR is conducting three interventional 
clinical trials to test the efficacy of measures to prevent and control spread of MDR 
organisms in intensive care units, surgical units, and rehabilitation centres, respectively.  
 
• Carbapenem resistance in food animal ecosystems: EFSA reviewed the information on the 
epidemiology of acquired resistance to carbapenems, including the genes coding for such 
resistance, in food-producing animals and food and identified possible means of preventing 
or minimising the further emergence and spread of carbapenemase-producing bacterial 
strains transmitted via the food chain, including consideration of the advantages and 
disadvantages of different options. Recommendations are given on how to prevent the 
emergence of resistant bacteria72. 
 
US activities 
 
− Control of Carbapenem-Resistant Enterobacteriaceae (CRE): Detection and prevention 
guidelines published in March 2009. Recent importation of NDM-1 and other novel CRE 
mechanisms has led to refocusing the public health response. Several states are currently 
assessing local epidemiology and prevention practices used by the healthcare delivery sector. 
 
− American Recovery and Reinvestment Act (ARRA): Funded state MRSA, C. difficile, and other 
multidrug-resistant organisms (MDRO) prevention collaborative programs that use 
standardised strategies and assessment instruments. See toolkits here.  
 
− CDC’s Prevention Epicenters (PE) Program: CDC’s Division of Healthcare Quality Promotion 
(DHQP) collaborates with academic investigators to address important scientific questions 
regarding the prevention of HAIs, antibiotic resistance, and other adverse events associated 
with healthcare. These Epicenters study topics such as MRSA, vancomycin-resistant 
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enterococci, and other multidrug-resistant bacterial pathogens; bloodstream infections; 
surgical site infections; ventilator-associated pneumonia; C. difficile; and catheter-associated 
urinary tract infections.  
 
− The Healthcare Infection Control Practices Advisory Committee (HICPAC): Fourteen external 
infection control experts provide advice and guidance to the CDC and HHS regarding the 
practice of healthcare infection control, strategies for surveillance, and prevention and 
control of HAIs in US healthcare facilities. One of the primary functions of the committee is 
to issue recommendations for preventing and controlling HAIs in the form of guidelines, 
resolutions, and informal communications.  
 
− A statewide collaborative to prevent infections caused by MDROs: CDC is conducting a 
statewide collaborative in Vermont that involves nearly all the acute and long-term care 
facilities in the state. This effort targets clusters of acute and long-term care facilities from 
the same areas and attempts to implement regional strategies for MDRO prevention. In 
addition, the effort will utilise electronic data collection to measure outcomes. The goal of 
this effort will be to both decrease transmission of MDROs already present in Vermont and to 
prevent the emergence of new MDROs. 
 
− A multistate collaborative to assess the dynamics of MDRO contamination in the healthcare 
environment and the impact of environmental cleaning and disinfection methods. CDC is 
working with state health departments in Illinois, Vermont, and Maryland to coordinate a 
prevention collaborative, which includes both acute care hospitals and nursing homes.  
 
C. Ongoing Activities – Training 
 
Joint activities 
 
− The ESCMID/SHEA Training Course in Hospital Epidemiology was first established in 1999 
and has been approved by the European Society of Clinical Microbiology and Infectious 
Diseases (ESCMID) and the Society for Healthcare Epidemiology of America (SHEA). This 
intensive training programme is intended for those working with infection control and 
hospital epidemiology. It covers epidemiology and infection control within the hospital 
setting. This course features international experts and offers basic, advanced, and applied 
modules. It is run each year, and, over the years, it has evolved into the leading European 
course in its field, with more than 1,000 alumni. 
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EU activities 
 
− TRICE (Infection control training needs assessment in the European Union) is a project 
funded by ECDC that reviewed information on human resources and training in infection 
control in European countries. TRICE identified a need to standardize infection control 
training in Europe and developed a core curriculum for this purpose. After assessing the 
training needs for infection control in Europe, ECDC proposes a strategy for basic training 
at the EU level in the area of infection control. In June 2013, ECDC published the core 
competencies for infection control and hospital hygiene professionals in the European 
Union73. TRICE recommended adoption and endorsement of the European Infection Control 
and Hospital Hygiene (IC/HH) Core Competencies. TRICE-IS is a ECDC-funded project 
building on the results of the TRICE project with the aim to implement a strategy to 
support the national/regional infection control/hospital hygiene training programmes in EU 
Member States, EEA/EFTA countries, and EU acceding countries. 
 
US activities 
 
− New tools to measure adherence to infection control recommendations in healthcare 
facilities: CDC is working with academic partners to develop an iPhone/iPod Touch application 
to assist observers (including patients) in evaluating adherence to recommended hand 
hygiene and isolation precaution practices. The application has been deployed in several 
CDC-led outbreak investigations and has been used by members of various prevention 
collaborative programs for consistent and efficient data collection by observers. 
   
− Preventing MRSA infections in VA medical centres: CDC is working with acute care VA 
medical centres nationwide in an effort to decrease MRSA HAIs. MRSA HAI rates declined 
24% in the non-ICU setting and 77% in the ICU setting, following full implementation of 
interventions. Analyses will include monitoring changes in the S. aureus antibiogram 
following implementation of the programme and an examination of factors that explain 
variability of impact among individual facilities.  
D. Ongoing activities – Campaigns 
 
Joint activities 
 
                                                     
73 http://ecdc.europa.eu/en/publications/publications/infection-control-core-competencies.pdf 
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− Participation in WHO Patient Safety Campaigns, e.g., hand hygiene and tackling AMR.  
 
US activities 
 
National MRSA Education Initiative: A campaign to help Americans better recognise and prevent 
MRSA skin infections through public service announcements and educational materials for 
healthcare providers. The initiative provides information that can help prevent the spread of MRSA, 
recognise infection, and treat those who are infected. 
 
E. Ongoing research activities – Vaccines 
 
US activities (NIH/NIAID) 
 
− CDC established three active research collaborations with vaccine developers for C. difficile 
infections to collect data and define the risks.  
− The National Institutes of Health (NIH), in collaboration with CDC and FDA, convened a 
workshop on how to overcome the challenges in S. aureus vaccine development with the 
objectives to discuss the lessons learned from recent Staph vaccine clinical trials, address the 
challenges in developing a Staph vaccine (basic, translational, and clinical research limitations) 
and potential ways to overcome them, and identify novel scientific approaches to Staph 
vaccine development 
(https://respond.niaid.nih.gov/conferences/staphvaccineworkshop2013/Pages/default.aspx) on 
7 June 2013 (Rockville, MD). 
 
EU activities (European Commission/DG RTD) 
 
Following a call published by DG RTD (HEALTH.2013.2.3.1-1: Drugs and vaccines for infections 
that have developed or are at the risk of developing significant antimicrobial resistance) within the 
7th Framework programme, several projects support the research and development of vaccines for 
bacterial infections have been funded.  
 
• NeoStrep  (Development of Group B Streptococcal vaccine to alleviate emerging antibiotic 
resistance through elimination of current prophylactic antibiotic strategies in GBS 
prevention) will develop a novel vaccine against Group B Streptococcal (GBS) infections, 
responsible for 50% of life-threatening infections in newborn babies. The goal is to provide 
a safe and effective alternative to current generally implemented antibiotic prophylaxis. 
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• BELLEROPHON (comBinig cELLular and humoral immunE RespOnses as a vaccine strategy 
against staPHhylOcoccus aureus pathogeN) will design, manufacture, and assess in a Phase 
I clinical study a novel S. aureus vaccine candidate targeting both the cellular and humoral 
responses. It is designed to be protective against both MRSA and more sensitive S. aureus 
strains. 
• CD-VAX (Oral Vaccination against Clostridium difficile Infection) will use a novel mucosal 
vaccine delivery system based on the use of inactivated Bacillus subtilis spores that express 
two different recombinant C. difficile antigens on their surface, a toxoid antigen, and a 
unique spore colonisation factor. The project will address its safety and immunogenicity in 
both preclinical and phase I clinical studies. 
 
3. Strategies to improve the pipeline of new  antibacterial drugs 
 
A. Ongoing research activities 
 
US activities (NIH/NIAID) 
 
Basic research 
 
− Investigator-initiated research grants comprise the bulk of NIH/NIAID funding. A complete 
list of funded AMRs grants can be found at the NIH RePORT website. Examples of AMR 
topics covered in NIH/NIAID’s grants portfolio are 
 
• Mechanisms of resistance 
• Antimicrobial, diagnostic, and vaccine target identification and characterisation 
• Discovery of new chemical entities with antimicrobial activity 
 
International investigators are eligible for most investigator-initiated grant mechanisms. 
 
− NIH/NIAID issues calls for applications (grants) and proposals (contracts) in specific targeted 
areas each year. A comprehensive and current list of these announcements can be found in 
the NIH Guide for Grants and Contracts. 
 
− NIH/NIAID has made a significant investment in genomic-related activities that provide 
genomic sequencing, functional genomics, bioinformatics, and proteomic resources and 
reagents to the scientific community. For example, scientists have sequenced the genomes of 
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more than 6500 bacterial strains, including 550 S. aureus, 425 Enterococcus species, 150 
Streptococcus pneumonia, and 265 Acinetobacter species. In addition, NIH/NIAID has 
initiated new genome sequencing studies of important antibiotic resistant bacterial 
pathogens, including sequencing the genomes of more than 500 CRE isolates. NIH/NIAID 
supports Bioinformatics Resource Centers that serve to collect, integrate, and provide open 
access to research data of microbial organisms in a user friendly format for the scientific 
community, including bioinformatics analysis capability and tools. These services are freely 
available to the international research community. More information can be found here.  
 
Translational research 
 
− NIH/NIAID provides a broad array of preclinical and clinical research resources and services 
to researchers in academia and industry designed to facilitate the movement of products 
from bench to bedside. By providing these critical services to the research community, 
NIH/NIAID can help to bridge gaps in the product development and lower the financial risks 
incurred by industry to develop novel antimicrobial drugs. These services are freely available 
to the international research community. More information can be found here.  
 
− NIAID’s Partnerships Program supports collaborative efforts and multidisciplinary approaches 
between academia and the pharmaceutical industry to advance candidate products or 
platform technologies through the product development pathway and has supported 
numerous grants addressing resistance since its inception in 2000. For example, in Fiscal 
Year (FY) 2012, NIAID awarded 12 phased innovation partnership awards under the 
“Targeting Resistance in Select Gram-Negative Pathogens” research initiative (RFA AI-11-
009). The partnership programme also featured initiatives to stimulate the development of 
new diagnostic technologies for resistant pathogens in 2004, 2006, and 2008. International 
institutions are eligible for partnership grants. Interested parties are encouraged to subscribe 
to NIAID’s funding newsletter to stay abreast of upcoming funding opportunities. 
 
Clinical research  
 
− NIAID supports clinical trials infrastructure focused primarily on evaluating new drugs 
through the Vaccine and Treatment Evaluation Units (VTEUs ) and the Phase I Clinical Trial 
Units for Therapeutics, as well as through investigator-initiated clinical trials. Each of these 
support mechanisms is available to the international research community. More information 
on funded NIAID clinical trials with relevance to AMR can be found here. 
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− NIAID is supporting clinical trials to inform the rational use of existing antimicrobial drugs to 
help limit the development of AMR. Since 2007, NIAID has made multiple awards for 
targeted clinical trials designed to help answer key questions about proper antimicrobial 
dose, treatment duration, and whether antimicrobial treatment is necessary in all cases. 
These trials are ongoing or in development. More information about the trials can be found 
at the following links: skin and soft tissue infections caused by CA-MRSA (2007); catheter-
related bacteremia and urinary tract infections (2009); gram-negative bacteremia and acute 
otitis media and community-acquired pneumonia (2010).  
 
− In June 2013, NIH/NIAID launched the Leadership Group for a Clinical Research Network on 
Antibacterial Resistance (ARLG), a major new clinical effort to address AMR. The ARLG has 
developed a clinical research agenda identifying the most important clinical questions in 
antibacterial resistance. Studies conducted by the ARLG may include clinical testing of new 
drugs to treat MDR gram-negative bacteria, evaluating diagnostic devices in clinical settings, 
evaluating the effectiveness of new antimicrobial stewardship programs, and optimizing 
treatment regimens to reduce the emergence of resistance 
 
EU activities (European Commission/DG RTD) 
 
− The European Commission (DG RTD) issued annual calls under the Seventh Framework 
Programme. In this programme, which runs from 2007 through 2013, antimicrobial drug 
resistance constitutes one of four areas in infectious diseases research. The other three 
areas target specific pathogens or groups of pathogens (the three poverty-related HIV, 
malaria, tuberculosis, the emerging [viral] epidemics and the neglected [tropical] infectious 
diseases). MDR-HIV and MDR-tuberculosis are exclusively considered under the area 
“HIV/AIDS, malaria and tuberculosis.” Although viral, fungal, and parasitic drug resistance 
are not excluded in “antimicrobial drug resistance,” most of the resistance problems are 
found in bacteria, which therefore constitute the bulk of the projects funded. 
 
Collaborative research projects funded under the EU Seventh Framework Programme for 
Research (FP7) address different topics related to AMR. Each project must have partners 
from at least three EU Member States (or associated countries) but may include non-EU 
partners. Research projects funded within the Health programme are open for US 
participation and US partners are eligible for funding (EU–NIH agreement on funding 
reciprocity). More information on international cooperation can be found here.  
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In general, research supported through this programme addresses one of the following 
broad areas: 
 
• Developing strategies for prudent/rational use of currently available drugs – 
Research projects in this area aim at slowing down the rise in resistance and reduce 
the spread of resistant microbes. 
• Developing novel antimicrobial therapies – Research projects in this area focus on 
new use of existing antibiotic drugs, the development of new antibiotic drugs, or the 
identification of new drug targets. 
• Developing new rapid cost-effective diagnostic tests – The development of 
diagnostic tests is required to aid diagnosis and to determine whether antibiotic 
drugs should be prescribed and which antibiotic drugs should be prescribed. 
• Validation of diagnostic tests – The validation of diagnostic tests is required to 
determine performance, robustness, sensitivity, reliability, etc. in the clinical setting. 
 
More information on research projects that are funded under both the Sixth and Seventh EU 
Framework Programmes can be found here.  
 
The work programme for 2011 featured several call topics in the area of AMR, which in that 
call was a priority area. Proposals were required to address research needs described in the 
following five call topics 
 
• Investigator-driven clinical trials of off-patent antibiotic drugs 
• Multidisciplinary research on the evolution and transfer of antibiotic resistance 
• Management of gram-negative multidrug-resistant infections 
• Development of multi-analytic diagnostic tests 
• Development of tools to control microbial biofilms with relevance to clinical drug 
resistance 
 
For the above listed call topics, 10 research projects have been funded. 
 
The work programme for 2012 featured a call topic on diagnostics for infectious diseases. 
This led to the funding of two projects that will develop diagnostic tools to detect bacteria 
and resistance markers. 
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AMR featured as a priority area in the work programme for 2013, which included a novel 
initiative to unlock the potential of small and medium-sized enterprises. Proposals were 
required to address research needs described in the following five call topics: 
 
• Development of drugs, vaccines, or novel therapies 
• Stratified approaches to antibacterial/antifungal treatment  
• Ecology and transfer of AMR throughout the food chain 
• Nanotherapeutics to treat bacterial infectious diseases 
 
For the above listed call topics, 15 research projects have been funded. More information on the 
funded projects can be found here. 
 
In March 2012, the Innovative Medicines Initiative (IMI) launched its first call for proposals under 
the ”New Drugs for Bad Bugs” (ND4BB) programme, a major public-private partnership effort to 
address bottlenecks in discovery and development of new antibiotic drugs. Seven ND4BB projects 
with a total committed budget of more than €600 million have since either started or are in 
preparatory phases. They have five principal aims: 1) to create a sustainable EU clinical 
investigator and laboratory network with the capacity to run large-scale antibiotic clinical trials; 2) 
to use that network for improved and more efficient clinical development of new antibiotic drug 
candidates; 3) to advance our understanding of the underlying science, notably penetration 
barriers, and efflux mechanisms in gram-negative bacteria; 4) to progress promising novel hit or 
lead molecules into early clinical development; and 5) to develop options for novel economic 
models of antibiotic research and development and responsible use of antibiotic drugs.  
EU Member States are coordinating their activities and pooling their national research in order to 
increase the effectiveness and impact of European public efforts. On this basis, a Joint 
Programming Initiative (JPI) entitled ”The Microbial Challenge - An Emerging Threat to Human 
Health” has been set up. The initiative involves 17 European countries plus Israel, and was 
recently joined by Canada and could be a good starting point for engaging in a global initiative. A 
first joint call with Canada was announced on 15 November, and the strategic research agenda of 
this JPI will be launched on 3 April 2014. 
The EU Seventh Framework Programme for Research ends in 2013, but research to combat AMR 
will also be supported in the new programme, Horizon 2020 (2014-2020). The first work 
programme for Horizon 2020 was launched on 11 December 2013, and this includes a topic to 
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support identification and control of new and emerging infectious diseases including those from 
antimicrobial/resistant pathogens74. 
 
B. Ongoing regulatory activities 
 
Joint activities 
 
− International Conference on Harmonisation (ICH): Through the ICH, the EMA and the US 
FDA have developed a number of guidance documents on  preclinical and clinical 
development of drugs. The available guidance documents75 include the following: 
 
• E8 General Considerations for Clinical Trials76 
• E9 Statistical Principles for Clinical Trials77 
• E10 Choice of Control Group and Related Issues in Clinical Trials78 
• E11 Clinical Investigation of Medicinal Products in the Pediatric Population79 
• E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential 
for Non-Antiarrhythmic Drugs80 
• ICH M3(R2), Nonclinical Safety Studies for the Conduct of Human Clinical Trials and 
Marketing Authorization for Pharmaceuticals81 
 
Of note is that the guidance documents listed above were developed by the ICH process – 
guidance documents that both the EMA and the US FDA rely on. In addition to these, there 
are also guidance documents on a wide range of other topics about drug development that 
serve as a valuable resource to persons who are interested in information on drug 
development. These resources include advice on manufacturing issues and a wide range of 
other topics. 
 
US activities (FDA) 
 
                                                     
74 http://ec.europa.eu/programmes/horizon2020/en/area/health 
75 Guidance Documents can be found at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm  
76 The Guidance Document E8 General Considerations for Clinical Trials is available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073132.pdf 
77 The Guidance Document E9 Statistical Principles for Clinical Trials is available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf 
78 The Guidance Document E10 Choice of Control Group and Related Issues in Clinical Trials is available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073139.pdf 
79 The Guidance Document, E11 Clinical Investigation of Medicinal Products in the Pediatric Population is available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073143.pdf 
80 The Guidance Document,  E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, is available 
at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf 
81 The Guidance Document, ICH M3(R2), Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for 
Pharmaceuticals, is available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf 
78 
 
Recent and current activities in the area of antibacterial drug development  
 
− The FDA has participated in a number of meetings held by public-private partnerships to 
address a number of important topics to facilitate the development of new antibacterial 
drugs. EMA, NIH/NIAID, and CDC have also participated in a number of these meetings. The 
meetings held by the Brookings Institution: Engelberg Center for Health Care Reform, the 
Foundations for the National Institutes of Health Biomarkers Consortium, and the Clinical 
Trials Transformation Initiative are listed below. 
− Brookings Institution: Engelberg Center for Health Care Reform - The Brookings 
Council on Antibacterial Drug Development has a goal to identify steps to address the 
major technical, regulatory, and financial barriers impeding antibacterial drug 
development. Meetings of the Council have included 
o Facilitating Antibacterial Drug Development; 9 May, 2012 
o Brookings Council on Antibacterial Drug Development Kick-Off Meeting; 30 
August, 2012 
o Incentives for Change: Addressing the Challenges in Antibacterial Drug 
Development; 27 February, 2013 
o Special Medical Use: Limited Use for Drugs Developed in an Expedited Manner 
to Meet an Unmet Medical Need; 1 August, 2013 
 
− Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium - The FNIH 
Biomarkers Consortium embarked on a project to identify clinical efficacy endpoints for 
clinical trials of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community-
Acquired Bacterial Pneumonia (CABP), and HABP/VABP. Meetings and accomplishments of 
the project team include the following: 
o First meeting of the project team for ABSSSI/CABP endpoints: focus on 
ABSSSI; 20 May, 2010 
o Follow-up meeting of the project team for ABSSSI/CABP endpoints: focus on 
CABP; 2 June, 2010 
o Discussion of endpoint development for additional indications, and preliminary 
results of the retrospective reviews of completed trials; 26 & 27 January, 2011 
o Discussion of interim efficacy endpoint recommendations for ABSSSI and 
CABP based on results of the retrospective reviews of completed trials; 8 July, 
2011 
o Recommendations to FDA for interim efficacy endpoints ABSSSI and CABP 
with the submission of comments to the docket for the draft guidance 
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documents ABSSSI and CABP; 26 August, 2011 and publication of “Progress 
on Developing Endpoints for Registrational Clinical Trials of Community-
Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure 
Infections: Update From the Biomarkers Consortium of the Foundation for the 
National Institutes of Health” by George H. Talbot, John H. Powers, Thomas R. 
Fleming, Judith A. Siuciak, John Bradley, Helen Boucher, and on behalf of the 
CABP-ABSSSI Project Team in Clin Infect Dis. (2012) 55 (8): 1114-1121 first 
published online 28 June, 2012. 
o First meeting of the project team for HABP/VABP endpoints; 24 April, 2013 
 
− Clinical Trials Transformation Initiative – The Accelerating Antibacterial Drug Development 
project has a goal of identifying challenges, exploring novel solutions, and issuing 
recommendations on speeding up the development of new antibacterial drugs. Meetings of 
the CTTI group include the following: 
o CTTI Think Tank on Unmet Medical Need and Hospital-Acquired and 
Ventilator-Associated Bacterial Pneumonia (HABP/VABP); 11 & 12 October, 
2012 
o Quality by Design in HABP/VABP trials; 22 & 23 April, 2013 
o Quality by Design in HABP/VABP trials; 29 August, 2013 (via teleconference): 
o Safety data collection in HABP/VABP trials; 12 November, 2013 
 
− The FDA has been updating its guidance documents to describe recommended clinical trial 
designs for studying antibacterial drugs. In some circumstances, the FDA has held public 
workshops to discuss the science or FDA Advisory Committee meetings and to get advice on 
the design of clinical trials for studying antibacterial drugs for selected conditions. The 
workshops and Advisory Committee meetings held to date are listed below. 
• FDA Advisory Committee Meetings Focusing on clinical trial designs 
o Community Acquired Bacterial Pneumonia; November 2011 
Hospital Acquired Bacterial Pneumonia / Ventilator-Associated Bacterial 
Pneumonia;  November 2011 
o Community Acquired Pneumonia April 2008; December 2009 
o Acute Bacterial Skin and Skin Structure Infections; November 2008 
• IDSA/FDA co-sponsored Community-Acquired Pneumonia (CAP) workshop; January 
2008 
• IDSA/ATS/ACCP/SCCM/FDA co-sponsored Hospital Acquired Pneumonia/Ventilator 
Associated Pneumonia workshop; March/April 2009 
80 
 
• IDSA/FDA/NIAID co-sponsored workshop on AMR; July 2010 
• FDA workshop – Issues in the Design and Conduct of Clinical Trials for Antibacterial 
Drug Development; August 2010 
• FDA workshop – Design of Clinical Trials of Aerosolized Antimicrobials for the 
Treatment of Cystic Fibrosis; September 2010 
 
− There have also been FDA Advisory Committee discussions on clinical trial design in the 
context of specific antibacterial drug products that informed recommendations on clinical trial 
designs. These efforts to date have resulted in publication of updated guidance documents 
on developing antibacterial drugs or non-inferiority clinical trial designs. The guidance 
documents published to date include the following: 
• Antibacterial Drug Products: Use of Noninferiority Studies to Support Approval: Final 
November 2010 
• Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment: Draft 
January 2014 
• Noninferiority Clinical Trials: Draft March 2010 
• Hospital Acquired Bacterial Pneumonia / Ventilator Associated Bacterial Pneumonia: 
Draft November 2010 
• Complicated Urinary Tract Infection: Draft February 2012 
• Acute Bacterial Exacerbation of Chronic Bronchitis in Patients with Chronic 
Obstructive Pulmonary Disease: Final September 2012 
• Acute Bacterial Otitis Media: Final October 2012 
• Acute Bacterial Sinusitis: Final October 2012 
• Complicated Intra-Abdominal Infections: Draft November 2012 
• Antibacterial Therapies for Patients With Unmet Medical Need for the Treatment of 
Serious Bacterial Diseases: Draft July 2013 
• Pulmonary Tuberculosis: Draft November 2013 
• Acute Bacterial Skin and Skin Structure Infection: Final October 2013 
 
− In addition to the updated guidance documents listed above, there are several guidance 
documents that are being developed, updated, or are planned for development82. The topic 
areas include the following: 
 
• Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial 
Pneumonia 
                                                     
82 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm 
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• Uncomplicated Gonorrhea 
• Complicated Urinary Tract infections 
• Complicated Intra-Abdominal Infections (cIAI) 
• Antibacterial Therapies for Patients with Unmet Medical Need for the Treatment of 
Serious Bacterial Infections 
 
− The FDA has also published a draft guidance document on noninferiority trials that provides 
information on the conceptual approach to noninferiority trials, recommendations on design 
of such trials, interpretation, and developing a noninferiority margin. In addition, for 
sponsors seeking guidance on trial designs for studying an antibacterial drug, the FDA 
division responsible for review of the product is available to meet with companies during 
product development to provide feedback and advice on their proposed development 
programme. 
 
Regulatory tools for drug development  
 
− FDA’s Center for Drug Evaluation and Research’s Pre-IND Program: Sponsors interested in 
developing a drug for treatment of a serious infection can contact the FDA and discuss their 
nonclinical and clinical development plans with the division responsible for the review of their 
product. CDER’s Pre-IND programme allows sponsors to receive direct feedback on their 
proposed submission of an IND, including the types of nonclinical studies that should 
accompany the IND. Sponsors have an opportunity to consider the recommendations they 
receive in planning their development programmes83.  
 
− Fast Track Designation: Companies that are developing a drug for the treatment of a serious 
disease that has the potential to address an unmet medical need can request fast track 
designation. The FDA developed fast track designation in order to facilitate development of 
such drugs84. Even if therapy already exists, a drug may still be granted fast track 
designation if advantages over existing therapy are evident, such as improved efficacy or a 
better safety profile. The level of evidence to support fast track designation is commensurate 
with the stage of development. Sponsors with a drug that has received fast track designation 
are encouraged to meet frequently with the Agency to discuss clinical development plans. 
                                                     
83 The Office of Antimicrobial maintains a Pre-IND Consultation website, which can be found at: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplicatio
n/Overview/default.htm 
84 Guidance for Industry: Fast Track Drug Development Programs — Designation, Development and Application Review. Available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079736.pdf 
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Sponsors may also submit completed sections of an NDA as part of a rolling review for the 
FDA to begin its evaluation before submission of the full marketing application. 
 
− Priority Review Designation: Under the Prescription Drug User Fee Act (PDUFA), a goal for a 
specific time frame to complete the review of an NDA is established. For a product that 
receives a standard review, the PDUFA goal for completing the review is 10 months. For 
drugs that offer a major advance in treatment or provide treatment where no therapy exists, 
the product may receive a priority review designation85. The goal for completing a priority 
review of an NDA is six months.  
 
− Qualified Infectious Disease Product Designation: Certain antibacterial or antifungal drugs 
intended for the treatment of serious or life-threatening infections may qualify for 
designation as a qualified infectious disease product (the Food and Drug Administration 
Safety and Innovation Act of 2012 [Public Law 112-144, Title VIII, section 801]). A 
designation as a qualified infectious disease product provides for regulatory incentives, such 
as fast track designation, priority review, and an extension of the drug’s exclusivity period for 
certain qualifying products. 
 
− Breakthrough Therapy Designation. An investigational drug that has preliminary clinical 
evidence indicating the potential for substantial improvement over existing therapies can be 
designated as a breakthrough therapy (section 506(a) of the FD&C Act, as added by section 
902 of the Food and Drug Administration Safety and Innovation Act of 2012). The 
designation conveys the fast track program features, as well as intensive FDA guidance on 
efficient drug development programs 
 
− Proposed Limited Population Antibacterial Drug (LPAD) Program. In December 2013, 
members of the US Congress introduced legislation86 to establish a new development 
program for LPAD. LPAD drugs would be approved to treat limited subsets of patients with 
serious or life-threatening manifestations of specific bacterial infections where few or no 
therapeutic options are available. Consistent with the particular benefit/risk profile that exists 
for such vulnerable patients, LPAD drugs’ safety and efficacy could be demonstrated based 
on more limited data than is required for traditional antibacterial drug approvals. The US 
Administration has not yet taken a position on the bill. However, FDA will work with Congress 
to improve the legislation, as requested. 
                                                     
85 Manual of Policies and Procedures, Center for Drug Evaluation and Research, MAPP 6020.3 Review Classification Policy: Priority (P) and Standard (S), 
available at: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/UCM082000.pdf  
86 H.R. 3742, the “Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013, introduced December 12, 2013.  
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EU activities (EMA) 
 
Recent and current activities in the area of antibacterial drug development   
 
− The core guidance document for the clinical development of antibacterial agents 
(CPMP/EWP/558/95 Rev2) was revised during 2009–2011. Before finalisation, a symposium 
was held in 1Q2011 at which regulators, industry and academia met to discuss the areas 
perceived to have particular implications for future development programmes. The draft 
revision carries a section specific to the development of new agents with potential to be 
clinically useful against multidrug-resistant bacteria and this will be one of the areas 
discussed at the symposium. 
 
− EMA has also developed an addendum to the core guidance on the evaluation of medicinal 
products indicated for treatment of bacterial infections in order to address the most critical 
expectations for commonly sought indications and to further refine the strategies for 
development of new antibacterial agents addressing unmet medical needs related to AMR. 
Following release of a draft document for consultation, a workshop has been held in 2012 
and a final version87 issued in November 2013. 
 
− EMA Infectious Disease Working Party (IDWP) has been established in order to oversee 
guideline development and to contribute as needed on any specific issue in the field of 
infectious diseases arising from committees’ discussions or scientific advice. In addition to 
this working party made up of regulators from some of the national agencies across the EU, 
an independent advisory group of experts in the field of infectious diseases may be called on 
to advise the CHMP and IDWP as considered necessary.   
 
− The EMA has in place a number of additional guidelines of high relevance to the 
development of antibacterial agents. It should be noted that the guidance regarding non-
inferiority margins is also currently under revision: 
 
• Guideline on the choice of non-inferiority margin (EMEA/CPMP/EWP/2158/99 Rev) 
• Points to consider on application with 1. Meta-analyses 2. One pivotal study 
(CPMP/EWP/2330/99).  
                                                     
87 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500153953.pdf 
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• Points to consider on the pharmacodynamic/pharmacokinetic relationship 
(CPMP/EWP/2655/99) 
• Guideline on clinical trials in small populations (CHMP/EWP/83561/2005) 
• Extrapolation of results from clinical studies conducted outside Europe to the EU 
population (CHMP/EWP/692702/08) 
 
− During the last two years, the EMA has collaborated with the European Centre for Disease 
Control (ECDC) to consider and publish an analysis of the gap between antibacterial drug 
development and emerging clinical need in light of increasing rates and types of antibacterial 
resistance. This report was presented and discussed at a meeting held in Stockholm in 
September 2009, which provided much of the impetus from the EU side for the development 
of TATFAR. 
 
Regulatory tools for drug development 
 
− Scientific advice: Scientific advice and protocol assistance is provided by the EMA to 
pharmaceutical companies. It is designed to speed up the development and availability of 
high-quality, effective, and acceptably safe medicines for the benefit of patients. Scientific 
advice (and protocol assistance – the special form of scientific advice available for the 
development of medicines for ‘orphan’ or rare diseases) can be requested either during the 
initial development of a medicinal product (i.e., before submission of a marketing-
authorisation application) or later on, during the post-authorisation phase. 
 
− The Scientific Advice Working Party (SAWP) is a standing Working Party of the Committee on 
Human Medicinal Products (CHMP) and is responsible for drafting scientific advice on any 
aspect of a drug development programme (including manufacture, non-clinical and clinical 
evaluations). Final advice, with or without the need for a discussion meeting with the 
sponsor, is issued after consideration by the CHMP and in a procedure that takes a maximum 
of 90 days. Protocol assistance is free of charge and scientific advice carries a reduced fee 
for small companies that meet certain criteria (Small Medium Size Enterprises – SMEs)88. 
 
− Accelerated assessment: Once a centralised application has been filed to EMA, the total 
clock-on days is limited to 210. On request from sponsors and at the discretion of the CHMP, 
the total review time may be shortened when the product in question is considered to have 
                                                     
88 EMA Scientific Advice guidance available on EMA website at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000049.jsp&murl=menus/regulations/regulations.jsp&mid=WC
0b01ac05800229b9  
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potential to treat a serious disease and/or fulfils an unmet medical need89. In case of the 
granting of a request for an accelerated assessment procedure, the EMA shall ensure that 
the opinion of the CHMP is given within 150 days. 
 
− Conditional marketing authorisation: In the case of certain categories of medicinal products, 
in order to meet unmet medical needs of patients and in the interests of public health, it may 
be necessary to grant marketing authorisations on the basis of less complete data than is 
normally the case and subject to specific obligations, i.e., granting ‘conditional marketing 
authorisations’. The categories concerned should be medicinal products that aim at the 
treatment, prevention or medical diagnosis of seriously debilitating or life-threatening 
diseases, or medicinal products to be used in emergency situations in response to public 
health threats recognised either by the WHO or by the community. 
 
− Although the data upon which an opinion on a conditional marketing authorisation is based 
may be less complete, the risk-benefit balance should be positive. Furthermore, the benefits 
to public health of making the medicinal product concerned immediately available on the 
market should outweigh the risk inherent in the fact that additional data are still required. 
The holder should be required to complete or initiate certain studies with a view to 
confirming that the risk-benefit balance is positive and resolving any questions relating to the 
quality, safety and efficacy of the product90. 
                                                     
89 CHMP Guideline on the procedure for accelerated assessment pursuant to article 14 (9) of regulation (EC) No 726/2004 available at: 
www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500004136  
90 Guideline on the scientific application and the practical arrangements necessary to implement commission regulation (EC) No 507/2006 on the 
conditional marketing authorisation for medicinal products for human use falling within the scope of regulation (EC) No 726/2004 available at: 
www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500004908www.ema.europa.eu/ema/pages/includes/documen
t/open_document.jsp?webContentId=WC500004908 
